Neurocognitive deficits in participants at clinical high-risk for psychosis: relationships to clinical symptoms and functioning by Mitchell, Lucy
 
 
 
 
 
 
 
 
 
Mitchell, Lucy (2018) Neurocognitive deficits in participants at clinical high-
risk for psychosis: relationships to clinical symptoms and functioning. 
MSc(R) thesis. 
 
https://theses.gla.ac.uk/41109/  
 
 
 
Copyright and moral rights for this work are retained by the author  
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge  
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author  
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author  
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses  
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
 
  
Neurocognitive Deficits in Participants at 
Clinical High-Risk for Psychosis: 
Relationships to Clinical Symptoms and 
Functioning 
 
 
 
Lucy Mitchell  
 
 
A thesis submitted in fulfilment of the requirements for the Degree of Master 
of Science (Research) 
 
 
 
School of Psychology  
College of Science and Engineering  
University of Glasgow 
 
 
 
September 2018 
 
 
 
 
 
 Abstract 
 
Background: Neurocognitive impairments are a core feature of schizophrenia (ScZ) contributing 
to ongoing psychopathology and poor psychosocial functioning. These deficits have been 
consistently observed before illness onset in individuals at clinical high risk for psychosis (CHR) 
suggesting that they may be an endophenotype of the disorder. Traditional CHR studies have 
recruited exclusively using clinical pathways however, it has been recently reported that the 
majority of individuals who present with a first episode of psychosis have not been seen by 
specialised prodromal services suggesting that these studies only capture a subgroup of CHR 
individuals (Ajnakina et al., 2017).  Few studies have included CHR individuals recruited from 
community pathways who may differ from those recruited clinically in the degree of 
neurocognitive impairment and clinical trajectory. Neurocognitive functioning in CHR individuals 
may also be influenced by the high prevalence of comorbid non-psychotic disorders experienced by 
the population. So far, few studies have addressed this question which may provide valuable 
information to improve functional and clinical outcome in those at-risk.  
Aim 1: To explore the degree of neurocognitive impairment in CHR-participants recruited from the 
general population and identify their relationship with positive symptom severity and functioning.  
Aim 2: To investigate the influence of comorbid non-psychotic disorders on neurocognitive 
functioning in CHR-participants by identifying the degree of neurocognitive impairment in a CHR-
negative group who scored below the CHR threshold but are characterised by non-psychotic 
disorders 
Aim 3: To explore the association between baseline neurocognitive functioning and clinical 
outcome at 12 months. 
Methods: The Youth Mental Health and Resilience Study (You-R) recruited CHR- and CHR-
negative participants from the general population using a unique web-based screening tool. At 
baseline neuropsychological tests together with functioning assessments were administered to 
healthy controls (N = 57), CHR-negative participants (N = 43), community recruited CHR- (N = 
110) and clinically recruited CHR-participants (N = 12).  CHR-participants received follow-up 
 assessments at 3 or 6 month intervals. At the 12 month assessment participants were categorised as 
remitters (CHR-R; N = 33), non-remitters (CHR-NR; N = 16) or converters (N = 1) depending on 
the change of their attenuated psychotic symptom status from the baseline to follow-up assessment. 
Results 1: Community recruited CHR-participants presented with small to moderate sized 
impairments in motor speed, processing speed, emotion recognition (response time) and attention 
by comparison to healthy controls. Within the community recruited CHR group emotion 
recognition (RT) predicted positive symptom severity while verbal memory, emotion recognition 
(RT) and the neurocomposite score significantly predicted functioning. 
Results 2: CHR-negative participants were not impaired by comparison to HC in any of the 
neuropsychology tests and they had a statistically significant better performance in processing 
speed by comparison to the CHR-positive group.   
Results 3: Overall, there was a high number of non-transitions and remissions at 12 months. 
Comparisons of baseline neurocognitive functioning revealed that non-remitters were statistically 
significantly more impaired in motor speed and emotion recognition (RT) than remitters. 
Moreover, remitters but not non-remitters performed similarly to healthy controls in a number of 
neuropsychological tests at baseline.  
Conclusions: Community recruited CHR-participants presented with neurocognitive impairments 
by comparison to healthy controls in domains highlighted by previous research using clinically 
recruited populations. These impairments were more pronounced in CHR individuals who had 
ongoing attenuated psychotic symptoms at 12 months compared to those who remitted. However, 
the high number of non-transitions and remissions questions if this was a group enriched for 
psychosis risk. Additionally, although the CHR-negative group presented with preserved 
neurocognitive functioning they had a lower prevalence of comorbid non-psychotic disorders than 
the CHR-positive group so the influence of comorbid non-psychotic disorders remains largely 
unknown.   
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Chapter 1  
Schizophrenia 
 
Schizophrenia (ScZ) is a severe and complex psychotic disorder that is associated with a number of 
cognitive, behavioural and affective abnormalities. Despite having a relatively low median 
population prevalence of 3.3 per 1000 (Saha, Chant, Welham & McGrath, 2005) ScZ was ranked in 
the top 25 leading causes of disability worldwide in 2013 (Vos et al., 2015). Those diagnosed with 
ScZ have a lower life expectancy contributed to by higher rates of comorbid illnesses such as 
coronary heart disease, stroke, type II diabetes, respiratory diseases and some cancers (Laursen, 
Nordentoft & Mortensen, 2014) and unnatural deaths including suicide (Charlson, Baxter, Dua, 
Degenhardt, Whiteford & Vos, 2015). This comes at a considerable societal and economic cost. A 
report by the Schizophrenia Commission found that in England this cost amounted to £11.8 billion 
per year (Andrews, Knapp, McCrone, Parsonage & Trachtenberg, 2012). This is because ScZ is a 
chronic and long-lasting condition with less than 14% recovering within the first 5 years of their 
first psychotic episode (Robinson, Woerner, McMeniman, Mendelowitz & Bilder, 2004) and only 
an additional 16% making a late phase recovery (Harrison et al., 2001). It is also common for 
individuals to have periods of stability and relapse due to environmental adversity or poor response 
to treatment (National Collaborating Centre for Mental Health UK, 2014). Although 
symptomatology and functioning varies considerably between individuals, the effects of the illness 
are often highly detrimental with only 5% to 15% of people with ScZ being employed 
(Schizophrenia Commission, 2012).  
1.1 Diagnosing Schizophrenia  
 
There are two competing taxonomies of mental disorders; the Diagnostic and Statistical Manual of 
Mental Disorders 5th Edition (DSM- 5; APA, 2000) and the International Statistical Classification 
of Diseases and Related Health Problems 10th Edition (ICD-10; WHO, 1992). A summary 
comparing the criteria required for a ScZ diagnosis for each assessment is reported in Table 1. The 
imminent release of the 11th edition of the ICD will see notable changes in some criteria with the 
aim of being more congruous with the DSM-5. However, differences regarding the length of 
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symptom duration and functional impairment will remain (Tandon et al., 2013) continuing to cause 
inconsistencies in diagnosis between clinicians  
 
 
 
1.2 Pathogenesis of Schizophrenia 
 
1.2.1 Neurodegenerative Hypothesis 
 
Kraepelin (1919) coined the label ‘dementia praecox’ after observing that patients had a 
progressive decline in their behavioural functioning which he attributed to ongoing deterioration of 
the brain anatomy (Jablensky, 2007). This led to the conceptualisation that ScZ was a 
neurodegenerative disorder. Some neuroimaging studies report findings of progressive changes in 
brain structures in those with ScZ (Andreasen, et al., 2011; Van Haren et al., 2008; Olabi, Ellison-
Table 1: DSM-5 and ICD-10 criteria for ScZ 
 Required clinical 
symptoms 
Length of 
symptoms 
Functioning Prodromal 
phase 
Exclusion criteria 
DSM-5  At least two of: 
hallucinations, delusions, 
disorganised speech (eg., 
frequent derailment or 
incoherence), grossly 
disorganised or catatonic 
behaviour, negative 
symptoms (i.e., diminished 
emotional expression or 
avolition)  
More than 6 
months  
Reduction in 
premorbid 
functioning in 
one (or more) 
major areas; 
work, 
interpersonal 
relations or self-
care 
 At least 6 
months 
Drug intoxication or 
withdrawal, concurrent 
major depressive or 
manic episodes, 
schizoaffective, bipolar 
or depressive disorder 
with psychotic features, 
overt brain disease 
ICD-10 At least one of: thought 
echo, thought 
insertion/withdrawal/broadca
st, passivity, delusional 
perception, third person 
auditory hallucination, 
running commentary, 
persistent bizarre delusions 
or two or more of:  
persistent hallucinations, 
thought disorder, catatonic 
behaviour, negative 
symptoms, significant 
behaviour change  
More than 1 
month  
N.A.  N.A.  Drug intoxication or 
withdrawal, mood 
disorders, 
schizoaffective disorder, 
overt brain disease 
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Wright, McIntosh). However, there are many difficulties in differentiating abnormal from normal 
ageing as numerous factors can alter the structure of the brain such as cannabis abuse (Martín-
Santos et al., 2010; Yücel et al., 2008;) and lifestyle factors such as the regularity of exercise 
(Colcombe et al., 2006; Pajonk et al., 2010) and antipsychotic medications (Ho, Andreasen, 
Ziebell, Pierson & Magnotta, 2011). Thus, it cannot be determined if psychosis results in an 
ongoing deterioration of brain structures.  
1.2.2 Neurodevelopmental Hypothesis 
 
Although not mutually exclusive, the neurodevelopmental hypothesis of ScZ is seen to be a 
competing theory of ScZ pathogenesis. It was first proposed by Scottish psychiatrist Thomas 
Clouston (1891) but was largely dismissed in favour of the neurodegenerative approach until its 
revival 30 years ago.  
Originally, it proposed that ScZ was the result of abnormal development caused by pre- or perinatal 
complications. Structural brain abnormalities in ventricle size and gyrification patterns observed in 
those diagnosed with ScZ were proposed to be caused by problems during foetal development like 
periventricular bleeding or hypoxia (Lewis & Murray, 1987; van Os & Kapur, 2009; Reveley, 
Clifford, Reveley & Murray, 1982). An insult to early development is supported as individuals with 
ScZ in adulthood have been found to have speech difficulties, delayed motor development, lower 
test performances and a solitary play preference during childhood compared to age-matched 
controls (Jones, Murray, Rodgers & Marmot, 1994). It has been proposed that pre- and perinatal 
risks alone cannot be used to predict the development of ScZ in adulthood and may indicate a more 
general susceptibility to future mental illness (Jones et al., 1994). However, some specificity has 
been reported as neurodevelopmental features and educational attainment were associated with 
psychosis but not affective or neurotic symptoms, which were found to be better predicted by social 
factors (Jones et al., 1994; Rodgers, 1990). 
Heritability rates of ScZ have been estimated as being around 80% (Cardno & Gottesman, 2000; 
Sullivan, Kendler & Neale, 2003) suggesting the importance of genetics in the development of the 
disorder. In line with the neurodevelopmental hypothesis it is proposed that these abnormalities 
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initiate a cascade of neural events disrupting early brain development leading to the emergence of 
psychotic symptoms in late adolescence and early adulthood (Birnbaum & Weinberger, 2017; 
Owen, O’Donovan, Thapar & Craddock, 2011). This has been supported by post-mortem studies 
that have reported abnormal brain changes mediated by brain gene expression which occur early in 
development and not at overt illness onset (Hill & Bray, 2012; Tao et al., 2014). Various candidate 
genes have been associated with the ScZ phenotype (Fatemi & Folsom, 2009) in addition to several 
large, rare copy number variants (CNVs; Owen, et al., 2011). However, CNVs specific to a severe 
psychosis phenotype have not been identified (Owen et al., 2011). Moreover, CNVs associated 
with ScZ overlap with neurodevelopmental disorders like autism, ADHD and learning disabilities 
suggesting a neurodevelopmental continuum of risk that results in distinct disorders when genetics 
converge with epigenetic and environmental risk factors (Birnbaum & Weinberger, 2017).  
1.2.3 Environmental Risk Factors 
 
A number of environmental risk factors have been identified that influence the development of 
ScZ. A meta-analysis found that those with psychosis were 2.7 times (95% CI = 1.90-3.88) more 
likely to have experienced childhood adversity than controls (Varese et al., 2012). This association 
was found to be related to all types of adversity investigated (abuse, neglect, parental death and 
bullying) and was dependent upon the extent and number of traumatic experiences. Varese and 
colleagues (2012) propose that the elimination of childhood adversities that they examined 
(assuming causality) could reduce the number of individuals diagnosed with psychosis by 33%.  
Further support for the impact of adversity comes from research illustrating the high prevalence of 
ScZ among immigrant populations who face persecution, social exclusion, poverty and social 
upheaval (Li, Law & Andermann, 2012). It has been observed that school children from a different 
ethnic background than the majority of students were more at risk of developing a psychotic 
disorder than their peers (van Nierop et al., 2014).  Additionally, psychosis has also been found to 
be more prevalent in urban populations (van Os, 2004). Zammit and colleagues (2010) suggest that 
this finding may be explained by the characteristics of the people living in these areas 
(compositional effects) rather than the places themselves (contextual effects) as there were 
differences in the frequency of psychosis between smaller neighbourhoods within the same cities. 
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The authors report that psychosis risk in certain neighbourhoods may be caused by the degree of 
social fragmentation. Together these findings tie in with the idea that social defeat is a core risk 
factor for psychosis (Selten & Cantor-Graae, 2005). Specifically, it is proposed that paranoia could 
develop due to persistent social adversity (Garety, Kuipers, Fowler, Freeman & Bebbington, 2001). 
Moreover, cannabis use has been linked to adverse effects on adolescent psychosocial development 
and mental health. The main component of cannabis, delta-9-tetrahydrocannabinol (THC) elicits 
temporary psychotic symptoms and impairs cognition in healthy volunteers (Morrison et al., 2009). 
The use of cannabinoids in adolescence has been found to increase the risk of developing psychosis 
in adulthood in a dose-related interaction (Radhakrishnan, Wilkinson & D’Souza, 2014), especially 
when it is of high potency and in synthetic forms (Murray, Quigley, Quattrone, Englund & Di 
Forti, 2016). It has been reported that individuals with a history of cannabis use in adolescence 
develop psychosis up to 2.7 years before individuals who do not use cannabis (Donoghue et al., 
2014). Another study proposed that 8% to 24% of cases of first episode psychosis could have been 
prevented without the impact of cannabis (Di Forti et al., 2015). 
1.2.4 Pathophysiological Theories 
 
A prominent hypothesis of the underlying cause of ScZ symptomology centres on the role of 
dopamine which came into focus following observations that positive symptoms in ScZ improved 
following the administration of drugs that blocked the reuptake of dopamine. This led to the 
prediction that there was excess transmission at dopamine receptors, in particular D2 receptors 
(Creese, Burt & Snyder, 1976; Seeman & Lee, 1975). However, this notion was not supported by 
later evidence that found no differences in the number of dopamine metabolites in the cerebrospinal 
fluid in those with ScZ by comparison to healthy controls (Widerlöv, 1988). Additionally, patients 
who were unresponsive to other antipsychotics responded well to clozapine despite its low affinity 
for D2 receptors (Peroutka & Synder, 1980; Richelson, 1984; Seeman, Lee & Chau Wong, 1976).   
Following these findings, technological advances in neurochemical imaging allowed for a more 
accurate measurement of dopamine levels. Studies reported an increased striatal dopamine 
synthesis capacity in those with ScZ (Meyer-Lindenberg et al., 2002; McGowan et al., 2004). This 
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abnormality is also present in first degree relatives of those with ScZ (Huttunen et al., 2008) and 
those in the prodromal phase of the illness (Howes, et al., 2009). This is proposed to be associated 
with adverse events in early life which make the dopamine system hyper-responsive to stressors 
later on. For example, those who report adverse childhood experiences including low maternal 
care, parental loss or separation, physical or sexual abuse during their childhood have an elevated 
striatal dopamine release in response to stress (Egerton et al., 2016; Pruessner, Champagne, 
Meaney & Dagher,2004). Adverse environmental conditions paired with a dysregulated dopamine 
system is proposed to create a vicious cycle where dopamine release is extended to non-threatening 
stimuli that promote psychotic beliefs (Howes & Murray, 2014).  
Impairments in dopaminergic functioning induce mainly positive psychotic symptoms as evidenced 
by studies that administered dopaminergic agonists such as amphetamine (Krystal et al., 2005). 
Following the administration of ketamine, an N-methyl-D-aspartate (NMDA) agonist, positive, 
negative and cognitive symptoms were elicited suggesting an overarching role of glutamate in the 
manifestation of psychotic symptoms (Morgan, Mofeez, Brandner, Bromley & Curran, 2004; Stone 
et al., 2012). Furthermore, NMDA receptors are located at brain circuits that regulate the release of 
dopamine suggesting that malfunctions in dopamine are mediated by an underlying glutamatergic 
dysfunction (Javitt, 2010).  
There are two primary neurotransmitters that account for 90% of all signal transmission; GABA 
which is inhibitory and glutamate which is excitatory. Impairments in both systems have been 
recorded via post-mortem and in vivo studies. NMDA, a subtype of glutamate receptor has been 
reported to hypofunction in those diagnosed with ScZ as evidenced by higher levels of its 
endogenous antagonist kynurenic acid in the cerebrospinal fluid and post-mortem brain in those 
with ScZ. (Linderholm et al., 2010). Evidence for dysfunctions in the GABA system are rooted  in 
observations of deficits in parvalbumin containing GABA neurons (Lewis, Curley, Glausier & 
Volk, 2012) and the decreased expression of GAD67 which plays a central role in the synthesis of 
GABA in those with ScZ (Curley et al., 2011; Ray, Weickert, Wyatt & Webster, 2011). 
Additionally, FEP participants have been found to have lower concentrations of GABA in the 
cerebrospinal fluid which was associated in a dose-response relationship with positive and negative 
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symptom severity and attentional deficits (Orhan, Fatouros-Bergman, Goiny, Malmqvist & Piehl, 
2018).  
Observations of glutamate and GABA dysfunction complement the dysconnectivity hypothesis of 
ScZ which posits that impairments in the functional integration of the brain underlie symptomology 
(Friston & Frith, 1995; Friston, 1998; Friston, Brown, Siemerkus & Stephan, 2016). Functional 
integration within and between brain regions is controlled by neural oscillations that coordinate 
neural activity (Buzsaki, 2006).  GABAergic neurons are integral to the initiation of high frequency 
oscillations and their synchronisation while glutamatergic connections mediate their strength, 
duration and long-range synchronisation (Traub et al., 2004; Wang & Buzsaki, 1996). Aberrant 
neural oscillations have been recorded in individuals with ScZ and have been found to be 
associated with positive symptoms, disorganised and negative symptoms and cognitive dysfunction 
(Lee, Williams, Haig & Gordon, 2003; Spencer et al., 2004; Uhlhaas et al., 2006).  Furthermore, in 
support of the neurodevelopmental hypothesis, there is suggested to be a critical developmental 
period where neuronal interactions have to be temporally precise and spatially focused enough to 
be supported by maturing cortical circuits. Pre- or postnatal insults may prevent this developmental 
process leading to dysregulated coordinated neural activity that result in the emergence of 
psychotic symptoms and cognitive impairment in late adolescence and early adulthood (Uhlhaas, 
Roux Rodriguez, Rotarska-Jagiela & Singer 2009).  
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Chapter 2  
The Psychosis Prodrome 
 
The neurodevelopmental hypothesis of psychosis predicts that deviations in cognitive, emotion and 
behavioural processes will be apparent before the onset of frank psychosis. Although these early 
symptoms of psychotic disorders have been observed for a long time the aspirations of effective 
early intervention have only emerged in the last 20 years. In 1932 the term prodromal was 
introduced by Mayer-Gross. ‘Prodrome’ means forerunner to an event and in medical terms the 
period before the onset of an illness (Yung & McGorry, 1996). Early anecdotal reports from studies 
of patients before the onset of frank psychosis reported that the most commonly described 
symptoms were; decreased concentration and attention, decreased drive and motivation, depressed 
mood, sleeping problems, anxiety, social withdrawal, suspiciousness, deterioration in role 
functioning and irritability (Yung et al., 1996).  Other studies have also identified similar non-
specific features of the prodromal phase such as reduced motivation, deterioration in role 
functioning and social withdrawal (Lencz, Smith, Auther, Correll & Cornblatt, 2004). Negative 
symptoms of depression and anxiety are common and likely to be the reason those at risk seek help 
in the first instance (Falkenberg et al., 2015; Fusar-Poli et al., 2012).   
Studies have reported that psychotic symptoms have been recorded in 8% to 14% of children aged 
11 - 13 years old (Kelleher & Cannon., 2011; Poulton, Caspi, Moffitt, Cannon, Murray & 
Harrington, 2000), a much higher prevalence than psychotic disorders reported in adulthood. The 
presence of psychotic symptoms should not always be treated as a precursor of psychotic disorders 
as it has been reported that 75-90% of psychotic experiences are transitory (van Os, Linscott, 
Myin-Germeys, Delespaul & Krabbendam, 2009) and do not interfere with functioning (Kelleher & 
Cannon, 2011).   
2.1 Identifying Individuals in the Prodromal Phase of Psychosis 
 
There are a number of different criteria that have been developed in order to detect symptoms of 
early psychosis. A recent review reported 22 measures for psychosis risk (Daneault & Stip, 2013). 
These instruments are often combined in research studies making it more challenging to define a 
9 
 
universal risk threshold (Yung, Nelson, Thompson & Wood, 2010). The most commonly used 
methods are the ultra-high-risk (UHR) and Basic Symptoms (BS) approaches which will be 
discussed in the following.  
In order to more effectively study the early symptoms of frank psychosis a ‘close-in’ strategy was 
developed by Yung & McGorry (1996). As it is unknown if these individuals will develop frank 
psychosis they are referred to as being ‘at-risk’ and not in the prodromal phase. Individuals are 
required to be between 15 - 30 years of age as this is the most common period for psychosis to 
emerge and be clinically help seeking. Depending on the frequency, duration and intensity of 
psychotic-like symptoms (ideas of reference, unusual perceptual experiences including body-
related illusions, paranoid ideation/mistrust, magical thinking and odd speech) presented 
participants would then be categorised into a suitable group (see Table 2). Using this criteria Yung 
and colleagues (2007) reported transition rates to psychosis of 34% within 6 months of referral and 
between 35% to 40% within twelve months. A more recent meta-analysis found that transition rates 
were found to be 36% during a 3-year follow-up (Fusar-Poli et al., 2012). The UHR criteria focuses 
on the onset of frank psychotic symptoms and not the development of a specific psychotic disorder 
like ScZ as using a non-specific outcome will identify more individuals at risk of future disability 
(Yung et. al., 2003). 
Another approach in detecting those who are at-risk is based on the work by Huber and Gross 
(1989). They identified the presence of Basic Symptoms (BS), which are subjectively experienced 
alterations of individual cognitive domains, such as: thought interference, preservation, pressure or 
blockages, disturbance of receptive language, decreased ability to discriminate between ideas and 
perception, unstable ideas of reference, derealisation, and visual or acoustic perceptual disturbances 
(Klosterkötter, Hellmich, Steinmeyer & Schultze-Lutter, 2001). These are distinct from psychotic 
symptoms as they are independent from abnormal thought content, reality testing and the individual 
is aware of their pathologic nature (Schultze-Lutter, 2009). Research has indicated that based on 
BS alone transition rates in CHR individuals can be as high as 54.9% within 4 years (Schmidt et 
al., 2015).  The individual can meet either the Cognitive Perceptive Basic Symptoms (COPER) or 
Cognitive Disturbances (COGDIS) criteria (see Table 2). 
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There is evidence for an initial prodromal state (EIPS) and a late initial prodromal state (LIPS). The 
sequence of symptom development starts with non-specific complaints and is followed by BS - 
which defines the EIPS (Ruhrmann, Schultze-Lutter & Klosterkotter, 2003). The LIPS is marked 
by attenuated psychotic symptoms (APS) and brief limited psychotic symptoms (BLIPS) as 
described in the UHR criteria. Schultze-Lutter and colleagues (2008) conducted a retrospective 
study of this symptomatic sequence in a sample of participants with first episode psychosis (FEP). 
They reported that almost all (98.4%) experienced prodromal symptoms and a third of participants 
reported BS earlier rather than simultaneously to or later than APS. This sequence was supported 
partially as most participants’ non-specific mental problems follow BS and/or APS before the onset 
of psychotic symptoms.  
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Table 2: Summary of UHR and BS assessment criteria 
 Psychotic 
symptoms 
intensity 
Psychotic 
symptoms 
frequency 
Functioning Duration Recency 
Ultra High Risk (UHR) Criteria 
 
Trait group 
 
 
 
 
 
APS group (a) 
subthreshold 
intensity  
 
 
APS group (b) 
subthreshold 
frequency  
 
 
BLIPS group 
 
None or 
subthreshold 
 
 
 
 
Subthreshold  
 
 
 
 
Threshold 
 
 
 
 
Threshold 
 
N.A. 
 
 
 
 
 
Several times per 
week  
 
 
 
>1 per month but 
less than several 
times per week 
 
 
Daily 
 
30% drop from 
premorbid levels  
OR 
GAF score <50  
 
 
N.A. 
 
 
 
 
N.A. 
 
 
 
 
N.A. 
 
>1 month 
 
 
>12 months 
 
 
12 months or 
less 
 
 
 
 
 
12 months or 
less 
 
 
 
 
 
 
<1 week, must 
have 
spontaneously 
resolved 
 
Within last 12 
months 
 
 
 
 
Within last 12 
months 
 
 
 
Within last 12 
months 
 
 
 
Within last 12 
months 
Basic Symptoms (BS) Criteria 
 
Cognitive 
Perceptive 
Basic 
Symptoms 
(COPER) 
 
Cognitive 
Disturbances 
(COGDIS) 
 
At least one 
basic symptom 
 
 
 
At least two  
 
 
Weekly 
 
 
 
 
Weekly 
 
N.A.  
 
 
 
 
N.A. 
 
12 months or 
more  
 
 
 
 
 
Within the last 
3 months 
 
 
 
Within the last 
3 months 
 
2.2 Transition from Subthreshold to Threshold Psychotic Symptoms 
 
Transitioning from attenuated psychotic symptoms to threshold psychotic symptoms is 
conceptualised by Yung and colleagues (1998) by the presence of at least one fully positive 
psychotic symptom several times a week for more than one week (Yung et al., 2003). The 
SIPS/SOPS criteria requires at least one fully positive psychotic symptom several times per week 
for at least one month or at least one fully positive symptom for at least one day if these symptoms 
are severely disorganized or dangerous (Miller et al., 2003). The differences between these two sets 
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of criteria highlight the inconsistencies in the diagnosis of psychosis threshold that depends largely 
on clinical judgement.  
A large number of individuals identified as ‘at-risk’ will never meet these criteria (Fusar-Poli et al., 
2013). The rates of transition to psychosis in the research has declined in recent studies. To 
determine the cause of falling transition rates Yung and colleagues (2007) investigated the 
available data from the PACE clinic in Australia.  They found no significant differences in the 
functioning and symptom level of UHR participants across studies. They reported that the lower 
transition rates reported in later studies were partially due to a reduction in the duration of 
symptoms of patients prior to intervention. This could be a consequence of supportive therapy and 
a prescription of antidepressants and/or anxiolytics that reduces stress and thus risk of transition. 
Thus, the non-transitioned sample could reflect a significant number of false-false-positives; 
individuals who would have transitioned if they had not received support. There may also be a 
number of false-positives; individuals who were not at real risk of transition. Additionally, Fusar-
Poli and colleagues (2013) put forward the possibility of a lead-time bias where those in the 
prodromal phase are detected earlier than they were in older studies giving the impression that 
transitions occur later.  
It has been argued that psychotic symptoms exist on a continuum and individuals should not be 
categorised dichotomously as ‘psychotic’ or ‘nonpsychotic’. Evidence to support this approach 
comes from the high prevalence of psychotic like experiences (5% to 8%) in healthy non-help 
seeking general population (van Os et. al., 2009). Furthermore, paranoid, schizoid and schizotypal 
personality disorders have a total prevalence of 1.6% (95% CI = 0.8 - 2.9) in the UK (Coid, Yang, 
Tyrer, Roberts & Ullrich, 2006) with most of these individuals not developing a psychotic disorder. 
Studies examining if psychotic symptoms lie on a continuum with psychotic illness have reported 
that psychotic symptoms group together in similar ways at clinical and subclinical levels, 
supporting the psychosis continuum hypothesis (Reininghaus, Priebe & Bentall, 2012; Reininghaus 
et al., 2015; Shevlin, McElroy, Bentall, Reininghause & Murphy, 2016).  
With the conceptualisation of ‘transitioning’ to psychosis researchers have looked for an 
underlying biological basis. A prominent area of interest has been grey matter. The majority of the 
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literature presents findings of gradual reductions grey matter as psychosis develops (Cannon et al., 
2015; McIntosh et al., 2011). However, a recent study reported a similar increase in volume and 
thickness in ARMS and FEP participants furthermore as the ARMS group is highly heterogeneous, 
containing individuals that will transition and false-positives it suggests that these abnormalities are 
a stable endophenotype for psychosis risk (Dukart et al., 2017). It has been proposed that the 
increase in grey matter observed in ARMS and FEP individuals may reflect cortical reorganisation 
and in turn resilience to psychosis onset and symptom severity (Palaniyappan, Das & Dempster, 
2017). This is supported by other studies that have reported an association between remission from 
baseline symptoms and an increase in grey matter (Lappin et al., 2014; Schaufelberger et al., 2011). 
Considering these findings, it suggests that changes in grey matter are associated with the severity 
of positive psychotic symptoms however cortical reorganisation may be possible in some 
individuals resulting in a decrease of symptom severity.   
Psychotic symptoms appear to lie on a continuum with the presence of transient symptoms in the 
general population through to the severe manifestation of ScZ at the other end of the spectrum. 
However, research has indicated that there are measureable biological differences in individuals 
with a larger degree of symptom severity suggesting that the distinction between ‘psychotic’ and 
‘not-psychotic’ is not completely arbitrary.  
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Chapter 3  
Cognitive Functioning in ScZ 
 
3.1 General vs Specific Deficit 
 
It has been proposed that the neurocognitive deficits observed in ScZ are underpinned by a general 
cognitive impairment (Dickinson et al., 2008; Keefe et al., 2006). Lower IQ scores with moderate 
to large effect sizes have been reported in those with ScZ by comparison to controls (Reichenberg 
& Harvey, 2007). However, IQ tests often do not assess all cognitive domains.  Factor analysis has 
generated seven distinct cognitive factors including: verbal learning & memory, visual learning & 
memory, working memory, attention/vigilance, reasoning/problem solving (executive functioning) 
speed of processing and social cognition which have been used to develop neurocognitive  batteries 
(Dickinson et al., 2008). Despite evidence that there are discrete neurocognitive domains, it has 
been reported that 64% of the variability in test performance was mediated by a general cognitive 
ability factor with individual contributions being made by processing speed and verbal memory 
(Dickinson et al., 2008). It has been proposed that rather than being mediated by a general 
cognitive ability factor, general cognitive impairments reflect the contribution of domain specific 
impairments (Gold, Hahn, Strauss & Waltz, 2009). This is supported as performance in 
neurocognitive assessments are highly correlated therefore deficits specific domains may mediate 
performance in other domains (Dickenson et al., 2008). Additionally, performance on some 
specific cognitive tasks have been reported as being preserved (Gold et al., 2009) adding to 
evidence that there is not simply a general cognitive impairment in ScZ.  
Specific tasks and domains have been reported to be particularly affected in ScZ. Processing speed 
as measured by the Digit Symbol Substitution Task (DSST) (Dickinson et al., 2008; Dickinson, 
Ramsey & Gold, 2007; Henry & Crawford, 2005), Stroop Test (Golden, 1978) and Trail Making 
Test A (Reitan & Wolfson 1985) have illustrated impairments with large effect sizes (Reichenberg 
et al., 2007). This is supported by neuroimaging studies that have found an association between 
slowed processing speed and white matter abnormalities in line with the dysconnectivity theory of 
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ScZ which posits that deficits of the disorder are a result of problems in the communication of 
brain regions rather than differences in local brain activity (Antonova et al., 2005). The DSST has 
reported more consistent and larger impairments than other measures of processing speed. 
However, these deficits have been argued to be overestimated (Knowles et al., 2010) and 
contributed to by deficits in working memory rather than processing speed (Barch & Ceaser, 2012).    
Psychomotor slowing has also been observed often in those with ScZ however it has not been 
studied to the same extent as other cognitive processes. Both tests that assess fine motor have found 
impairments in those with ScZ by comparison to controls (Dickinson et al., 2007; Heinrichs & 
Zakzanis) and have been found to be associated with dopaminergic striatal activity (Yang, Yu, 
Yeh, Chiu, Chen & Lee, 2004). These impairments have been associated with a modest effect to 
depressive or negative symptoms like apathy or motivational problems (Holthausen, Wiersma, 
Knegtering & Van den Bosch, 1999). Furthermore, they may reflect an underlying deficit in 
processing speed although factor analysis has identified two distinct symptom domains in those 
with ScZ (Bilder et al., 2002; Hobart, Goldberg, Barko & Gold, 1999; Morrens et al unpublished 
data in Morrens et al., 2006). More research is required to be able to identify the underlying causes 
of psychomotor slowing in those with ScZ.  
Assessments of attention and vigilance have also been observed to be impaired in ScZ patients with 
large effect sizes (Reichenberg et al., 2007). In particular, involuntary attention (Sereno & 
Holzman, 1996) and attentional control impairments are altered in ScZ participants (Fuller et al., 
2006). The specificity of these deficits to ScZ symptomology has been questioned as a similar 
pattern has been observed in affective disorders so this may not be a strong marker for the disorder 
(Sereno et al., 1995). Additionally, these problems are thought to be rooted in executive 
functioning (Kalkstein et al., 2010). Executive functions are higher-order cognitive abilities that 
direct decision making and skills like volition, motivation, self-awareness, planning, initiating 
purposeful behaviour, inhibiting inappropriate responses, abstract reasoning and mental flexibility. 
These abilities are linked to the frontal lobes, in particular the prefrontal cortex (Lezak, 2004) 
which has been reported to show dysfunctional activation during tasks of executive function in 
individual’s diagnoses with ScZ (Minzenberg, Laird, Thelen, Carter & Glahn, 2009). ScZ patients 
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present with a number of clinical symptoms that are suggestive of executive functioning 
impairments such as reduced spontaneity, avolition, mental rigidity and impaired social judgement. 
Tasks used to assess specific aspects of executive functioning such as rule learning and cognitive 
flexibility in the Wisconsin Card Sorting Test (WCST; Heaton, 1981), selective attention and the 
ability to inhibit habitual responses in the Stroop Test and visual attention and task-switching in the 
Trail Making Task B (Reitan et al., 1985) have all been found to be impaired with large effect sizes 
in those with ScZ by comparison to controls (Reichenberg et al., 2007). Those with ScZ have 
additionally been found to be significantly more impaired than other psychiatric groups (Johnson-
Selfridge & Zalewski, 2001) suggesting the importance of neurocognitive impairments in the 
symptomology of ScZ.  
Verbal learning and memory deficits are impairments in the ability to encode and retain verbally 
presented information which are typically assessed using list learning tasks such as the California 
Verbal Learning Test (CVLT). Large deficits for immediate and delayed recall have been observed 
in those with ScZ who perform approximately one standard deviation or more below healthy 
controls (Dickinson et al., 2007). Visual learning and memory have also demonstrated impairments 
but not to the same extent (Aleman, Hijman, de Haan & Kahn, 1999). Impairments in working 
memory are also present with large effect sizes in particular when information has to be 
manipulated rather than only maintained (Aleman et al., 1999; Dickinson et al., 2008; Lee & Park, 
2005).  Similar findings of specific skills within domains having more pronounced impairments 
have been recorded in assessments of verbal fluency. Here, impairments in letter fluency but not 
semantic fluency has been observed in those with ScZ (Dickinson et al., 2007; Henry et al., 2005; 
Bokat and Goldberg, 2003).  
The majority of those with ScZ will experience cognitive impairment but not everyone. Palmer and 
colleagues (1997) reported that 27% of ScZ patients and 85% of healthy controls were assessed as 
being not impaired in a clinical neurocognitive assessment. Similarly, Dickinson and colleagues 
(2007) reported that 27% of those with ScZ had a normal performance in the DSST. In these 
studies, more information is required to determine whether neurocognition reduced from premorbid 
levels. This gap has been addressed Kravariti and colleagues (2009) who report of three cognitive 
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profiles that emerged from their sample. A ‘high-functioning’ group (22%) who scored within the 
normal range on global IQ and neurocognitive assessments but still retained deficits of a small 
effect in verbal memory, working memory and executive functioning and a moderate effect in 
processing speed. A deteriorating group (37%) who had below average intellectual functioning that 
declined from their premorbid ability and the stable group (19%) who had below average 
intellectual ability before symptom onset which maintained. These findings suggest different 
trajectories in the development of ScZ not all of which are associated with impairments in 
neurocognition.  
3.2 Social Cognition 
 
Social cognition is an underlying mechanism used to navigate the social world (Penn, Sanna & 
Roberts, 2008). Emotional experience has been reported as being largely intact in ScZ (Cohen & 
Minor, 2010; Taylor et al., 2012). However, emotion regulation is thought to be disrupted as it has 
been reported that negative emotions increase in response to neutral and pleasant stimuli (Cohen et 
al., 2010).  A proposed explanation of such findings is that cognitive reappraisal strategies are 
being used less frequently in those with ScZ (Henry, Rendell, Green, McDonald & O’Donnell, 
2008; Horan, Hajcak, Wynn & Green, 2013).  
The perception of social cues has also been reported to be impaired: individuals with ScZ have 
deficits in affective facial processing (Delvecchio. Sugranyes &  Grangou, 2013; Taylor, et al., 
2012) and emotional prosody (Kantrowitz et al., 2011; Leitman et al., 2007) but not non-affective 
face processing (Bortolon, Capdevielle & Raffard, 2015) and non-emotional prosody (Murphy & 
Cutting, 1990; Pijnenborg et al., 2007).These impairments in the interpretation of social 
information have been proposed to exacerbate delusional symptoms, lead to social withdrawal and 
impair functioning (Fett, Viechtbaur, Penn, van Os & Krabbendam, 2011; Green, Hellemann, 
Horan, Lee & Wynn, 2012). 
Theory of mind (ToM) deficits have also been consistently recorded in ScZ (Bora, Yucel & 
Pantelis, 2009; Sprong, Schothorst, Vos, Hox & van Engeland, 2007) and have been reported to be 
associated with hypoactivation in the ventromedial PFC (vmPFC) and orbitofrontal cortex when 
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engaged in tasks which required participants to consider another person’s perspective to correctly 
identify objects (Eack, Wojtalik, Newhill, Keshavan & Phillips, 2013) and in the medial prefrontal 
cortex (mPFC) and bilateral temporoparietal junction (TPJ) when reasoning with another person’s 
beliefs (de Achával et al., 2012; Dodell-Feder, Tully, Lincoln & Hooker, 2014). Hyperactivation of 
the same areas has been found in ScZ patients who have preserved ToM abilities (de Achával et al., 
2012; Brune et al., 2008) suggesting that they are able to engage compensatory mechanisms (Green 
et al., 2015). However, the hyperactivation of these systems has been associated with the 
development of paranoid symptoms where individuals ‘over-mentalise’ causing them to ascribe the 
incorrect intentions of others (Blakemore et al., 2003; Frith, 2004).   
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Chapter 4  
Cognition in those ‘At-Risk’ of Psychosis 
 
The neurodevelopmental model of ScZ predicts that impairments in cognition will be present 
before the onset of frank psychotic symptoms. A better understanding of the pattern and onset of 
impairment together with its relationship to symptomatology could lead to a more accurate 
identification of individuals at true risk of transition. The following will review methods and results 
from previous research that have investigated the extent of neurocognitive deficits in those at-risk.  
4.1 Genetic Risk 
 
As ScZ is highly heritable, neurocognition has been examined in the unaffected relatives of ScZ 
patients via cross-sectional and longitudinal studies to determine if deficits are an endophenotype 
of the illness. Impairments by comparison to healthy controls in the domains of verbal memory 
recall, executive function, attention (Sitskoorn et al., 2004), working memory, episodic memory 
(Delawalla et al., 2006), perceptual motor speed, verbal ability and language (Byrne et al., 2003) 
have been observed in a dose-response relationship with genetic risk (Johnstone, Lawrie & 
Cosway, 2002).  However, the size of these impairments may be overestimated as participants 
included were at an age where transitions could still occur although, a study that included older, 
unaffected parents of individuals with ScZ reported significant neurocognitive impairments by 
comparison to control couples (Appels et al., 2003). Furthermore, despite not presenting positive 
psychotic symptomatology unaffected relatives may meet the criteria for schizotypal traits and 
negative symptoms (Delawalla et al., 2006; Chen et al., 2009) which may contribute to impaired 
neurocognition.   
Longitudinal studies in genetically high risk individuals have observed that some neurocognitive  
impairments appear to be stable and related to genetic vulnerability (O’Connor, Harris, McIntosh, 
Owns, Lawrie & Johnstone, 2009) while some emerge concurrently with the development of 
psychotic symptoms (Cosway et al., 2000) or are more severe when the individual also has 
schizotypal traits (Keshavan et al., 2005). These findings complement neuroimaging studies that 
reported small prefrontal lobes and thalami in asymptomatic unaffected relatives and further 
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reductions in the temporal lobe in individuals who developed psychotic symptoms (Johnstone et 
al., 2002). Additionally, performance in executive functioning and verbal learning and memory 
tasks in unaffected relatives has been reported to be mediated by IQ scores, which was not 
observed in healthy controls (Byrne et al., 1999) highlighting its utility at a protective factor.  
Overall, studies have observed neurocognitive impairment in relatives of individuals with ScZ 
suggesting that neurocognitive impairment is an endophenotype to the illness. However, as the 
impairments observed here are not to the same degree as those presented by individuals with ScZ it 
suggests an association with symptomatology.  
4.2 Clinical Risk 
 
Although studies of individuals with genetic risk have highlighted the presence of neurocognitive 
impairment in the absence of positive symptomatology, longitudinal studies using only this 
criterion are limited because of their long length and low transition rates (5 - 10%) (Pukrop & 
Klosterkötter, 2010). Studies that require participants to present with below threshold psychotic 
symptoms and impaired functioning may highlight a subgroup that is at a higher risk of transition. 
In a recent meta-analysis Hauser and colleagues (2017) highlighted mild to moderate impairments 
in attention/vigilance, speed of processing, verbal learning, social cognition and working memory 
that were intermediary between healthy controls and FEP participants. Impairments in processing 
speed were the most consistent between studies whilst performance on measures of attention, 
verbal memory and learning and verbal fluency were mixed. Additionally, spatial working 
memory, visual memory and general intellectual functioning were found to be generally preserved 
in high risk samples although there are some exceptions. These findings generally support the 
results from previous analyses (Bora et al., 2014; Giuliano et al., 2012). Any inconsistences 
between studies may stem from differences in the categorisation of neurocognitive assessments into 
domains, for instance verbal fluency in some studies has been considered a neurocognitive domain 
in its own right while in other studies it has been grouped under executive functions, executive and 
attention, executive functions and working memory or processing speed (Pukrop et al., 2010).  
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Analyses have also been conducted at the test level which are more easily comparable between 
studies. The most robust impairments are in the DSST (Bora et al., 2014; Fusar-Poli et al., 2012; 
Hauser et al., 2017), consistent with the ScZ literature (e.g. Dickenson, Mary, Ramsey & Gold, 
2007). Impairments were also consistently observed in CPT and the WCST (preservation errors) 
(Bora et al., 2014; Fusar-Poli et al., 2012; Hauser et al., 2017) and preserved ability in the Finger 
Tapping Tests (Fusar-Poli et al., 2012; Hauser et al., 2017). However, mixed findings were 
detected in other tasks for example deficits in both the TMT A and TMT B were reported by two 
meta-analyses (Bora et al., 2014; Hauser et al., 2017) but another observed impairments in only 
TMT A (Fusar-Poli et al., 2012). Similarly, deficits in both the immediate and delayed recall have 
been observed in the CVLT in one meta-analysis (Hauser et al., 2017) but impairments in only the 
immediate recall have been observed in another (Fusar-Poli et al., 2012).  
Inconsistencies between studies may be accounted for by differences in ages (Glahn et al., 2013), 
gender (Walder et al., 2013), years of education (Keefe et al., 2004), comorbid disorders and 
number of false positives in high risk groups. Furthermore, differences between groups may occur 
through the choice of assessment criteria. A number of tools have been utilised, the most common 
assessments are the BS and UHR however other studies have used the DSM-IV criteria for 
schizotypal personality disorder (Walder, Mittal, Trotman, McMillan & Walker, 2008), negative 
symptoms (Eastvold, Heaton & Cadenhead, 2007; Smith, Park & Cornblatt, 2006) and DSM 
prodromal criteria (Gschwandtner et al., 2003) to identify clinically at-risk individuals. This could 
result in the inclusions of distinct groups of participants with different clinical profiles and perhaps 
neurocognitive impairment as a result. For example, those identified using the UHR criteria have 
been reported to have more pronounced impairments in attention (Pukrop et al., 2006) working 
memory, verbal learning and memory (Fromman et al., 2010) by comparison to those with BS. In 
addition to highlighting a possible explanation of the inconsistencies between studies, these 
findings additionally address important questions regarding the etiology of ScZ as they imply an 
association between the increasing severity of positive symptoms and neurocognitive deterioration 
suggesting the use of neurocognition as a marker of impending psychosis onset. 
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4.3 The Role of Cognition in Transition to Psychosis  
 
Longitudinal studies have compared baseline neurocognitive performance between converters and 
non-converters to frank psychosis. In a recent meta-analysis, converters at baseline have been 
reported to have poorer performances by comparison to non-converters in the domains for 
attention/vigilance, speed of processing and verbal and visual learning but not executive 
functioning or working memory (Bora et al., 2014; De Herdt et al., 2013; Fusar-Poli et al., 2013; 
Hauser et al., 2017). At test level, Hauser and colleagues (2017) report that the tests with the 
highest discriminatory power were the Rey-Osterrieth Complex Figure Test (ROCFT), Controlled 
Oral Word Association Test (COWAT) and the CVLT. Significant differences found in the 
COWAT have been supported (Giuliano et al., 2011) but the impairment reported in the Letter 
Number Sequencing Test was not replicated in a previous study (Bora et al., 2014). Although 
statistically significant differences have been reported there is still a considerable overlap in the 
neurocognitive ability of converters and non-converters (Bora et al., 2014; Hauser et al., 2017) 
which may be accounted for by the ongoing risk of psychosis in non-converters suggesting the 
need for longer follow-up periods.  
Furthermore, although there is evidence of baseline differences in neurocognitive performance 
between converters and non-converters, it has not been determined if they are reliable in predicting 
transition to psychosis. Studies have reported that including neurocognitive  variables like IQ, 
processing speed, verbal learning, memory or verbal fluency together with clinical variables 
increased the predictive power of the model (Addington et al., 2016; Cannon et al., 2016; Corblatt 
et al., 2015, Michel et al., 2014; Metzler et al., 2016; Ziermans et al., 2013) but did not 
independently predict transition to psychosis. Additionally, it has been proposed that 
neurocognitive predictors may be better at specifically predicting ScZ than other psychotic illnesses 
because those diagnosed tend to have more severe neurocognitive impairment (Bora et al., 2014). 
However, one study reported no differences in those at-risk who went on to develop ScZ and 
affective psychosis (Olvet et al., 2010).  
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4.4 Beyond Transitional Outcomes  
 
Transition rates have been the main outcome parameter in at-risk studies however two-thirds of at-
risk individuals will not meet the threshold for psychosis (Fusar-Poli et al., 2012). These 
individuals may continue to have persistent attenuated psychotic symptoms and/or non-psychotic 
disorders (Lin et al., 2015; Simon et al., 2013) that could continue to negatively impact functioning.  
This is supported by the observation that 51% of at-risk individuals with the poorest functional 
outcome at 7 years did not develop a psychotic disorder (Lin et al., 2011). It has been considered 
that the at-risk criteria may highlight individuals who are also at risk for other non-psychotic, long 
lasting mental health problems that require intervention (Lin et al., 2015).  Thus, research should 
additionally consider what factors contribute to poor functional outcomes as well as what predicts 
transition.  
4.5 The Role of Cognition and Functional Outcome  
 
Functional outcomes are typically measured by the ability to live independently, the degree of 
social and family burden, employment status, interpersonal and social functioning and quality of 
life (Shrivastava, Johnston, Shah & Bureau, 2010).  The association of neurocognition and 
functional outcome has been studied considerably less in at risk populations although poor 
functioning and neurocognitive impairments have both been consistently observed independently 
(Brewer et al., 2006). Studying this potential association in at-risk groups is advantageous because 
functioning in chronic ScZ is confounded by the effects of medication treatment, hospitalisations, 
relapse and multiple episodes. Furthermore, a greater understanding of this potential interaction in 
at-risk groups could also improve targets for early intervention.  
A long term follow-up using functioning outcomes revealed larger neurocognitive deficits in those 
with poor functioning, assessed using the SOFAS and Quality of Life Scale, regardless of 
transitional status (Lin et al., 2011). Specifically these impairments were observed in verbal 
learning and memory, verbal fluency, basic attention and processing speed but not global cognition. 
However, only logical memory was able to successfully predict a poor functioning outcome. 
Another study, reported that baseline performance in the DSST could predict functional outcome 
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assessed using the SOFAS, after controlling for IQ and baseline functioning (Allot et al., 2018). 
When social and role functioning were assessed independently role functioning was predicted by 
global cognition, verbal memory (Carrión et al., 2013; Meyer et al., 2014), motor disturbances 
(Carrión et al., 2013) and social functioning by processing speed (Carrión et al., 2013) and 
executive functioning (Eslami, Jashan & Cadenhead, 2011). 
Furthermore, it has been reported that negative symptoms may mediate the association between 
neurocognition and role functioning (Glenthøj et al., 2018; Meyer et al., 2014). This suggests that 
both neurocognitive deficits and negative symptoms may both be suitable targets for intervention in 
at-risk groups in order to improve functional outcome. Functional outcome may additionally be 
affected by the prevalence of comorbid non-psychotic disorder (Lin et al., 2015), although 
elsewhere it has been proposed that anxiety and depressive symptoms do not influence functioning 
in at-risk groups (Cotter et al., 2014) suggesting the need for further research.   
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Chapter 5  
 Rationale, Aims and Hypotheses for the Current Study 
 
Cognitive impairments are frequently reported in CHR populations by comparison to healthy 
controls (Bora et al., 2014; Giuliano et al., 2012; Hauser et al., 2017) however, the majority of 
studies have recruited exclusively from clinical pathways. It was recently observed that the 
majority of individuals who present with a first episode of psychosis have not been seen by 
specialised prodromal services (Ajnakina et al., 2017) suggesting that clinically recruited CHR-
participants only capture a subgroup of at-risk individuals. The limited research conducted with 
community recruited CHR-participants has yielded mixed findings with one study suggesting they 
are similarly symptomatic (Platz et al., 2006) and another reporting higher levels of functioning and 
lower levels of positive symptom severity (Mills et al., 2017). To the best of our knowledge 
neurocognitive functioning has not been investigated in community recruited CHR-participants.  
 
Aim 1: To explore the degree of neurocognitive impairment CHR-participants recruited from the 
general population and identify their relationship with positive symptom severity and functioning. 
 
Hypothesis 1: CHR-participants recruited from the general population will have cognitive 
impairments by comparison to healthy controls. 
Hypothesis 2: Cognitive functioning in community recruited CHR-participants will not be 
significantly associated with positive symptom severity.  
 Hypothesis 3: Cognitive functioning in community recruited CHR-participants will be positively 
associated with psychosocial functioning.  
 
CHR individuals in addition to experiencing positive and negative symptomatology are typically 
diagnosed with comorbid psychiatric disorders, primarily anxiety, depression and substance abuse 
that are proposed to influence ongoing psychopathology and functioning (Fusar-Poli, Nelson, 
Valmaggia, Yung & McGuire, 2012). However, the influence of non-psychotic symptomatology on 
cognitive functioning in CHR individuals is largely unexplored. A recent study using a ‘help-
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seeking control group’ recruited from clinical pathways reported deficits in processing speed 
(Carrion et al., 2018), suggesting subthreshold CHR individuals may also experience cognitive 
deficits by comparison to healthy controls.  
 
Aim 2: To investigate the influence of comorbid non-psychotic disorders on neurocognitive 
functioning in CHR-participants by identifying the degree of neurocognitive impairment in a CHR-
negative group who scored below the CHR threshold but are characterised by non-psychotic 
disorders 
 
Hypothesis 4: The CHR-negative group will experience cognitive impairments, specifically in 
processing speed, by comparison to healthy controls but not to the same extent as CHR-participants 
who met the positive symptom threshold.  
 
Neurocognitive functioning at baseline has been reported to significantly predict clinical outcome 
alongside clinical variables in CHR populations. To the best of our knowledge, a longitudinal study 
has not been conducted with CHR-participants recruited from the community so the prevalence of 
clinical trajectories and their association with baseline neurocognitive functioning in this group is 
unknown. Typically, the categorisation of clinical outcome of CHR-participants has been limited to 
converters and non-converters to psychosis. However, non-converter groups remain heterogeneous 
including both remitters and non-remitters of attenuated psychotic symptoms. In their study with 
clinically recruited CHR individuals, Lee and colleagues (2014) reported that remitters but not non-
remitters performed similarly to healthy controls in baseline neurocognitive assessments suggesting 
their potential utility in predicting remission.  
 
Aim 3: To explore the association between baseline neurocognitive functioning and clinical 
outcome at 12 months.  
Hypothesis 5: Non-remitters at 12 months will have more pronounced cognitive impairments at 
baseline compared to remitters who will perform similarly to healthy controls.  
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Chapter 6  
Methodology 
 
6.1 Setting 
 
The data used for the current study was derived from the Youth Mental Health and Resilience 
(YouR) study (Uhlhaas, Gajwani, Gross, Gumley, Lawrie & Schwannauer, 2017) and is funded by 
the Medical Research Council (MRC). Recruitment for this study began in October 2014 and is 
scheduled to finish in Spring 2019.  
6.2 Participants 
 
Three groups of participants aged 16 - 35 years old will be used in this analysis; a clinical high risk 
group (CHR-positive; N = 122) who met the UHR and/or COGDIS/COPER criteria, a clinical high 
risk negative (CHR-negative; N = 43) group who scored below threshold for UHR and SPI-A 
criteria but were characterised by psychiatric comorbidity and heathy controls (HC; N = 57) who 
do not have any DSM-IV disorder, current substance abuse and first degree relative with psychosis. 
Additional exclusion criteria for all participants included having an existing neurological disorder, 
metal implants in the body, pregnancy or a current suicide plan.  
Participants were recruited through a web-based screening tool (see http://www.your-study.org.uk) 
which they were invited to via e-mail, flyers, posters and general practioner (GP) letters. 
Specifically, email invitations were sent to colleges and universities in Glasgow and Edinburgh, 
posters and flyers were available from NHS clinics and public transportation and letters were sent 
to potentially suitable participants identified on GP databases. Informed consent for the web 
screening was provided online, followed by 2 questionnaires: (a) the 16-item version of the 
Prodromal Questionnaire (PQ-16) and (b) a 9-item questionnaire of perceptual and cognitive 
aberrations (PCA) that was developed to assess BS. The PQ-16 was developed by Ising and 
colleagues (2012) from the 92-item prodromal questionnaire (PQ) (Loewy, Bearden, Johnson, 
Raine & Cannon, 2005) and has a high sensitivity (87%) and specificity (87%) with the CAARMS. 
Items for the PCA were derived from existing patient descriptions of cognitive and perceptual 
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experiences (Uhlhaas & Mishara, 2007) and items from the SPI-A (Schultze-Lutter, Addington, 
Ruhrmann & Klosterkötter, 2007). Participants were asked to provide ratings based on their 
experiences in the last 12 months. Potential CHR-positive participants had to meet the cut off 
criteria of 6 or more positively answered questions on the PQ (Isling et al., 2012) and 3 or more on 
the PCA to be invited for further clinical assessment.  
Clinically recruited CHR-positive participants were gathered via NHS patient’s services in NHS 
Greater Glasgow and Clyde and NHS Lothian, NHS First Episode Psychosis Services, Community 
Mental Health Teams (CMHTs), Primary Care Mental Health Teams (PCMHTs), Clinical 
Psychology Services, Community Adolescent Mental Health Services (CAMHS) and Non-
Governmental Mental Health Organisation’s. In total there are 12 (10%) CHR-positive recruited 
from a clinical route and 85 (78%) from the general population..   
All participants were informed that they were free to withdraw from the study at any point and that 
this will not affect the care or treatment that they receive. For completion of the initial online 
screening questionnaire, participants were entered into a prize draw to win an iPad. Following 
consent to take part in the study they were paid £6 per hour.  
6.3 Procedure 
 
6.3.1 Screening Interview  
 
Demographic information was obtained verbally including age, gender, years of education, family 
history of mental illness and suicidality. To establish CHR criteria the positive scale of the 
CAARMS (Yung et al., 2005) and COGDIS/COPER items from the SPI-A (Schlutze-Lutter et al., 
2007) were administered through trained research assistants and MSc/PhD level researchers. Inter-
rater reliability meetings were held monthly to ensure consistency in the interpretation and scoring 
of symptoms between researchers. Participants were recruited into the CHR-positive group if they 
met a) SPI-A COGDIS/COPER-criteria b) ARMS attenuated psychosis group (subthreshold 
psychotic syndrome present in the last year without a decline in functioning) c) ARMS 
vulnerability group (family history of psychosis plus a 30 % drop in GAF) or d) ARMS BLIPs-
group (brief limited intermittent psychotic symptoms).  
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The M.I.N.I. International Neuropsychiatric Interview (M.I.N.I 6.0) (Hergueta et al., 1998), Global 
Assessment of Functioning Scale (GAF; American Psychiatric Association, 1994) and Social and 
Role Functioning Scales (Cornblatt et al., 2007) were also administered.   
6.3.2 Neurocognitive Assessment  
 
Neurocognitive assessments included the Brief Assessment of Cognition in ScZ Battery (BACS; 
Keefe et al., 2004) as well as specific tasks from the University of Pennsylvania computerized 
neurocognitive testing battery (PennCNB; Moore et al., 2015). Additionally, premorbid IQ was 
estimated using the National Adult Reading Test (NART; Nelson & Willison, 1991) and a visual 
acuity test were administered.  
6.3.3 Follow-up Assessments  
 
CHR-positive participants had a follow-up assessment over the phone or in person every 3 - 6 
months for 36 months to administer the positive scale of the CAARMS in addition to the Social 
and Role Functioning Scale at the 6, 12 and 24-month assessment.  
6.4 Measures 
 
6.4.1 Psychopathology and Symptom Measures 
 
Comprehensive Assessment of At-Risk Mental States (CAARMS; Yung et al., 2005): Semi-
structured interview used to assess the presence and level of psychotic symptoms (see Chapter 2). 
Schizophrenia Proneness Instrument Adult Version (SPI-A; Schlutze-Lutter et al., 2007): 
Specialised instrument to assess the presence of BS (see Chapter 2). 
Mini-International Neuropsychiatric Interview (M.I.N.I 6.0; Hergueta et al., 1998): Structured 
psychiatric interview, used primarily in a research setting to diagnose DSM-IV and ICD-10 
disorders. Validated to the Structured Clinical Interview for DSM-III-R, Patient Version and the 
Composite International Diagnostic Interview. 
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6.4.2 Neurocognitive Measures 
 
Brief Assessment of Cognition (BACS; Keefe et al., 2004): A 30-minute pen-and-paper battery that 
assesses the following domains: verbal memory and learning, working memory, motor speed, 
verbal fluency (semantic and letter), processing speed and executive functioning. A composite 
score is calculated by averaging all of the six tasks and then calculating a z-score. The following 
tests are described in the following in order of their presentation.  
Verbal Memory, List-learning Task: A list of 15 words was read aloud and participants had to 
recall as many as possible. This procedure was repeated for 5 trials.  
Working Memory, Digit Sequencing Task: A sequence of numbers which gradually increase in 
length every 4 trials was read aloud, the participants had to repeat the sequence back in order from 
the lowest to highest number.  
Motor Speed, Token Motor Task: Participants were presented with 100 tokens that they had to pick 
up two at a time and put back into the empty container in 60 seconds.  
Semantic Fluency, Category Instances Task:  In 60 seconds participants had to produce as many 
different words as possible within the category of animals.  
Letter Fluency, Controlled Oral Word Association Task: In 60 seconds participants had to say as 
many words as possible that began with the letter ‘F’ and in the second trial, ‘S’.  
Processing Speed, Digit Symbol Substitution Test (DSST): Participants were presented with a key 
that matched unique but non-meaningful set of symbols that were each assigned to a number from 
1 – 9. They had to fill in a blank response sheet below using the key in 90 seconds.  
Executive Functioning, Tower of London (A) Task: Participants were presented with two images of 
different coloured balls arranged on three pegs of different sizes.  They were asked to respond how 
many moves it would take in the fewest possible moves to make the arrangement in image ‘A’ look 
like the arrangement in image ‘B’.  
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University of Pennsylvania Computerised Neurocognitive Testing Battery (PennCNB; Moore et al., 
2014):  A computerised neurocognitive testing battery to assess the following domains: 
attention/vigilance, working memory and emotional recognition. Performance was assessed in each 
test using an accuracy score and the response time (RT). The following describes the tests used to 
assess each domain in the order of presentation.  
Attention/Vigilance, Penn Continuous Performance Test (PCPT): Vertical and horizontal lines 
flashed onto the screen. Participants had to respond by pressing the spacebar when the lines were 
arranged in the shape of a complete number and in the second half, a complete letter.  
Working Memory, Penn Letter N-Back Test (PLNB): A series of letters individually flashed onto 
the computer screen. There were 3 conditions, in the first (0-back) participants had to press the 
spacebar when presented with the assigned target letter. In the second (1-back) and third (2-back) 
conditions they had to respond when the letter presented was the same as the previous letter or was 
the same as the two previous letters, respectively.  
Emotion Recognition, Emotion Recognition Test (ERT): Faces flashed onto the computer screen 
and the participants had to assign the correct emotion from a choice of five (happy, sad, anger, fear 
or no expression). 
National Adult Reading Tests (NART; Nelson et al., 1991): A single word, oral reading test of 50 
items used to assess premorbid intelligence. Scores are converted to estimate performance, verbal 
and full IQ using the Wechsler Adult Intelligence Scale-Revised (WAIS-R; Wechsler, 1981).  
6.4.3 Functioning Measures  
 
Global Assessment of Functioning (GAF; American Psychiatric Association, 1994): Assesses 
functioning in the psychological, social and occupational domains. Scores are rated from 1 – 100, 
with 1-10 signifying persistent danger and 91-100 superior functioning.   
Global Assessment of Functioning Scale, GF: Social and GF: Role. (Cornblatt et al., 2007): The 
two scales range from 1 to 10, with 10 being superior functioning and 1 extreme dysfunction. 
Scores reflect the highest and lowest level of functioning in the past year and lowest in the past 
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month. Both these scales are useful and distinct from GAF scores as they assess social and role 
functioning independently from each other and psychotic symptoms.  
The Global Functioning: Social examines the quantity and quality of peer relationships, age-
appropriate intimate relationships, family relationships and assesses if there is any conflict. There is 
a focus on assessing age-appropriate interactions outside of the family. When social contact is only 
coming from family members this will set a limit on how high the individual can score (1 to 3). For 
example, a score of 7 which signifies mild impairments in social functioning would be assigned to 
a 16 to 18-year-old who had both close and casual friends, is dating but have some problems 
resolving peer conflict. An individual who would be classified as having a major impairment and a 
score 4 would have no close friends, significant peer conflict and infrequent family contact.  
The Global Functioning: Role assesses performance at school, work or as a homemaker, depending 
on age. Scores are given with consideration to the demands of the role, level of independence or 
how much support they require. Again someone would be given a score of 7 if they achieved pass 
grades (‘D’) in school unsupported or ‘C’ grades with support for example extra time in exams. 
Someone of a similar age would be given a 4 score if they are failing all classes in mainstream 
school or passing with major support in place.  
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Chapter 7  
Statistical Analysis 
 
7.1 Baseline Analysis  
 
All statistical analyses were performed using SPSS version 24. When there were more than 2 
groups, continuous variables were analysed using a one-way ANOVA or Kruskal–Wallis test. If 
the homogeneity of variances assumption was violated following a one-way ANOVA, Welch’s F 
was reported. The Hochberg’s GT2 test was used post hoc for ANOVA analyses because of large 
differences in sample sizes. The Games-Howell was used for Welch. Hedge’s g effect sizes were 
calculated for both. Following a statistically significant result from the Kruskal-Wallis test 
significant pair-wise comparisons were identified using the adjusted p-values to reduce the risk of 
Type I error.  
When there were two groups, continuous variables that met the assumption of normality were 
analysed using an independent t-test or Mann-Whitney U test if this was violated. Categorical 
variables were analysed using a chi-square if all the assumptions were met and Fisher’s exact test if 
they were not. A Hedge’s g effect size was calculated following an independent t-test. An effect 
size for a significant Mann-Whitney U test was calculated by using the following equation 
(Rosenthal, 1991, p. 19).   
𝑟𝑟 = 𝑧𝑧
√𝑁𝑁
 
Where z is the z-score generated by SPSS and N is the total number of participants.  
7.2 Demographic Characteristics  
 
At baseline there was a sample of 57 healthy controls (HC), 43 clinically at-risk negative (CHR-
negative) and 122 clinically at-risk positive participants (CHR-positive). All groups were matched 
with respect to age and sex. See Table 3 for a full report of the demographic statistical 
comparisons. Briefly, a statistically significant difference, using the Hochberg’s GT2 test, existed 
between HC and CHR-positive groups as well as the CHR-negative and CHR positive groups in 
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the number of years of education with CHR-positive participants reporting less years than both 
groups. 
A Fisher’s exact test also revealed statistically significant differences between groups in the 
number of participants on mediation with 46.5% of CHR-negative and 51% of CHR-positive 
reporting that they currently take medication. Similarly, there was a high number of CHR-negative 
(63%) and CHR-positive (95%) who met the criteria for at least one other DSM/ICD psychiatric 
disorder as measured by the MINI.  
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     Table 3: Baseline Demographic and Clinical Characteristics of HC, CHR-negative and CHR-positive Participants 
Characteristic HC (N = 57) CHR-negative (N = 
43) 
CHR-positive (N = 
122) 
df Statistic p Significant post-hoc comparisons 
Age (years), M ± SD 22.44 ± 3.42 23.16 ± 4.96 21.59 ± 4.25 2, 98 2.13** 0.12  
Gender, N female (%) 39 (68) 29 (67) 90 (74)  0.90* 0.64  
Years of education, M ± SD 16.54 ± 2.97 16.56 ± 3.57 15.17 ± 3.19 2, 219 5.04 0.01 HC vs CHR-positive, CHR-negative vs CHR-
positive 
GAF, median, range 88 (67 – 97) 70 (43 – 94) 58 (21 – 95) 2 H = 112.87 <0.01 HV vs CHR-negative, CHR-positive, CHR-
negative vs CHR-positive 
CAARMS Severity, median, range 0 (0 – 12) 6 (0 – 24) 28 (0 – 72) 2 H = 140.10 <0.01  
GF: Social, median, range 9 (8 – 10) 8 (6 – 9) 8 (5 – 10) 2 H = 73.24 <0.01 HC vs CHR-negative, CHR-positive,  CHR-
negative vs CHR-positive 
GF: Role, median, range 9 (5 – 9) 8 (5 – 9) 8 (4 – 9) 2 H = 54.25  <0.01 HC vs CHR-negative, CHR-positive, CHR-
negative vs CHR-positive 
NART: Full IQ 114.19 ± 6.05 114.02 ± 6.22 114.19 ± 5.79 2, 209 F = 0.11 0.89  
NART: Verbal IQ 114.10 ± 6.63 113.84 ± 6.83 114.02 ± 6.41 2, 209 F = 0.03 0.97  
NART: Performance IQ 113.06 ± 4.77 112.81 ± 4.87 112.95 ± 4.50  2, 209 F = 0.02 0.98  
Medication, N (%) 1 (2) 20 (46.5) 62 (51)  52.61* <0.01  
Anti-psychotic 0 (0) 1 (3) 1 (10)     
Mood stabiliser 0 (0) 0 (0) 1 (1)     
Anti-depressant 0 (0) 11 (26) 26 (21)     
Other 1 (2) 6 (14) 15 (12)     
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Table continued HC CHR-negative CHR-positive df Statistic p Significant post-hoc comparisons 
Multiple 0 (0) 2 (6) 19 (15)     
Diagnosis, N (%) 5 (9) 27 (63) 116  (95) 3 142.14* <0.01  
Anxiety disorders 2 (3.5) 20 (46.5) 106 (87) 
   
 
Mood disorders 0 (0) 10 (23) 61 (50) 
   
 
Eating disorders 0 (0) 1 (2) 13 (11) 
   
 
Suicide Risk 1 (2) 11 (26) 62 (51) 
   
 
Alcohol Dependence/Abuse 2 (3.5) 10 (23) 35 (29) 
   
 
Substance Dependence/Abuse 0 (0) 2 (5) 16 (13) 
   
 
     *Fishers Test, ** Welch’s F 
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A Kruskal Wallis test found statistically significant difference between all pairs in social and role 
functioning, with CHR-positive participants having the lowest functioning. As the social and role 
functioning scores are nominal variables the frequency of each of the reported categories were also 
considered. Participants were classified as having good functioning if they scored above 6 (mild 
impairments to superior functioning) or poor functioning if they scored 6 or less (moderate 
impairments to extreme dysfunction).  In the HC group, 2% had poor role functioning compared to 
2% of CHR-negative and 17% of CHR-positive. Similarly, 0% of HC had poor social functioning 
compared to 5% of CHR-negative and 15% of CHR-positive.   
7.3 Cognitive Functioning 
 
7.3.1 BACS 
 
For each participant the individual score from each test was standardised by age and gender from a 
sample of 100 participants (Keefe et al., 2008) to produce z-scores and a composite score which are 
reported in Table 4.  
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   Table 4: Neurocognitive Performance of HC, CHR-negative and CHR-positive Participants 
 HC CHR-negative CHR-positive     
 N M ± SD N M ± SD N M ± SD df Statistic P Significant post-hoc comparisons 
     BACS     
Verbal Memory  57 0.08 ± 1.20 43 0.21 ± 1.30 122 -0.30 ± 1.52 2, 219 F = 2.80 0.06  
Working Memory 57 -0.22 ± 0.77 43 -0.08 ± 0.86 122 -0.27 ±1.00 2, 219 F = 0.78 0.46  
Motor Speed 57 0.28 ± 1.19 43 -0.25 ± 1.10 122 -0.64 ±1.41 2, 219 F = 9.78 <0.01 HC vs CHR-positive 
Verbal Fluency 56 0.47 ± 1.27 43 0.19 ± 1.02 122 0.24 ± 1.25  2, 218 0.88 0.41  
Processing Speed 56 0.68 ± 1.13 43 0.69 ± 1.28 122 0.03 ± 1.20 2, 219 8.15 <0.01 HC vs CHR-positive, CHR-negative vs 
CHR-positive 
Executive Functioning   57 0.27 ± 0.75 43 0.27 ± 0.89 120 0.19 ± 1.01 2, 217 0.19 0.83  
Composite Score  57 0.41 ± 0.80 43 0.26 ±1.02 122 -0.21 ±1.29 2, 219 6.93 0.01 HC vs CHR-positive 
     Penn CNB     
Emotion Recognition 57 0 ± 1 43 -0.19 ±0.91 121 -0.15 ± 1.09 2, 218 0.55 0.58  
Emotion Recognition (RT) 57 0 ± 1 43 -0.18 ± 1.36 121 -0.55 ±1.61 2, 218 3.22 0.04 HC vs CHR-positive 
Working Memory  57 0 ± 1 43 -0.24 ± 1.28 118 -0.34 ±1.44 2, 106 *1.94 0.15  
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*Welch’s  F
Table continued  HC  CHR-
negative 
 CHR-
positive 
    
 N M ± SD N M ± SD N M ± SD df F P Significant post hoc comparisons 
Working Memory (RT) 57 0 ± 1  43 0.11 ±1.02 120 0.08 ± 0.76 2, 217 0.24 0.78  
Attention 57 0 ± 1 43 -0.23 ± 2.73 119 -0.77 ± 2.74 2, 98 *3.76 0.03 HC vs CHR-positive 
Attention (RT) 57 0 ±1  43 0.25 ±0.98 121 0.13 ± 0.84 2, 218 0.96 0.38  
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In the BACS composite score, the CHR-positive group had a significantly lower score, following a 
Hochberg’s GT2 test post hoc, by comparison to HC with a medium effect size (g = 0.53).   
Analysis at the test level using the Hochberg’s GT2 post-hoc test revealed that motor speed was 
impaired in the CHR-positive group by comparison to HC with a medium effect size (g = 0.68). 
Similarly, processing speed was impaired in CHR-positive were impaired by comparison to HC (g 
= 0.55) and CHR-negative (g = 0.53) both with medium effect sizes.  
To investigate the association between processing speed and motor speed a Spearman’s correlation 
analysis was carried out. Performance on these two tasks were statistically significantly correlated 
for CHR-positive participants, rs = .33 and HC, rs = .30 but not CHR-negative, rs = .28.  
Statistically significant differences were additionally found between the CHR-positive and the 
BACS standardised controls. The CHR-positive group had impairments in the domains of verbal 
memory (g = 0.23), working memory (g = 0.27), motor speed (g = 0.51) and performed better in 
domains of verbal fluency (g = 0.21) and executive functioning (g = 0.19) with small to medium 
effect sizes.  
7.3.2 Penn CNB 
 
Scores in the Penn CNB were standardised to the YouR HC group to produce z-scores which are 
illustrated in Table 4. For each test an accuracy score (A) and reaction time (RT) were reported, the 
z-score for the latter was multiplied by -1 so a negative score for all scores signify a poorer score 
and a positive score, a better performance.  
Following a Hochberg GT2 post-hoc analysis it was found that CHR-positive participants 
performed statistically significantly worse compared to HC in the CPT-A (Attention, g = 0.37) and 
ERT-RT (g = 0.41) specifically for ‘happy’ faces (g = 0.57) with small to medium effect sizes. See 
Appendix C for a full report of emotion specific responses between groups.   
Figures 1 and 2 illustrate the Hedge’s g effect sizes found between the HC and the experimental 
groups in the BACS and the Penn CNB, respectively.  Error bars illustrate standard error (SE) 
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Error bars indicate standard errors of the mean. Effect sizes classified as small (0.2), medium (0.5) and large (0.8) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: VM = verbal memory, WM = working memory, MS = motor speed, VF = verbal fluency, PS = processing speed, EF = executive functioning, CS = composite score 
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Figure 1: BACS: Effect sizes between HC and CHR-negative, CHR-positive  
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 Error bars indicate standard errors of the mean. Effect sizes classified as small (0.2), medium (0.5) and large (0.8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations:  ERT–A = emotion recognition test accuracy score, ERT-RT = emotion recognition test reaction time, WM-A = working memory accuracy score, WM-RT = working memory reaction time, ATT-A = 
attention/vigilance accuracy score, ATT-RT = attention/vigilance reaction time 
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Figure 2: Penn CNB: Effect sizes between HC and CHR-negative, CHR-positive  
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7.4 CHR Subgroups 
 
Within the CHR-positive group there were 31 (26%) participants who met only the BS criteria, 38 
(32%) who met only the UHR criteria and 48 (41%) who met both the UHR + BS criteria. See 
Appendix B for a summary of the clinical, functioning and neurocognitive characteristics of these 
groups. There were no statistically significant differences between the BS, UHR and BS+UHR 
groups in measures of functioning. 
A statistically significant difference between UHR and BS + UHR was found following a 
Hochberg GT2 post hoc comparison with the UHR group performing worse with a medium effect 
size (g = -0.59). Comparisons to the HC group found that all groups performed statistically 
significantly worse than HC in motor speed with medium to large effect sizes (HC vs BS: g = -
0.61, HC vs UHR: g = -1.11, HC vs BS+UHR: g = -0.70).  Only the UHR group performed 
statistically worse in attention (g = -0.64), processing speed (g = -0.68) and had a lower composite 
score (g = -0.82) with medium to large effect sizes.  
7.5 Comparison of Clinically and Community Recruited CHR Groups  
 
Within the CHR group 90% (N = 110) were recruited from the general population (CHR-community) 
and 10% (N = 12) were recruited through clinical pathways (CHR-clinical). There were no 
statistically significant differences in CAARMS severity, GAF scores or social functioning between 
these two groups at baseline following a Mann-Whitney U test. The CHR-clinical group was 
statistically significantly impaired in role functioning was a small effect size (r = -0.19) by 
comparison to the CHR-community group. See Appendix A for a summary of clinical characteristics 
of these groups.  
Neurocognitive performance between CHR-clinical, CHR-community and HC was compared using 
a one-way ANOVA analysis. There were no statistically significant differences between performance 
in the CHR-clinical and CHR-community recruited participants. Post-hoc comparisons using the 
Hochberg GT2 revealed statistically significant impairments in both groups in motor speed and 
processing speed and Games-Howell, a lower composite score. However, the CHR-clinical group 
had larger impairments (motor speed: g = -1.14, processing speed: g = -1.32, composite scores: g = 
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-1.32) than the CHR-community group (motor speed: g = -0.64, processing speed: g = -0.48, 
composite score: g = -0.49). The CHR-community group had additional impairments with small 
effect sizes in the emotion recognition (RT; g = -0.35) and attention (g = -0.32) compared to HC that 
were not observed in the CHR-clinical group.  
7.6 Predicting Baseline Positive Symptom Severity and Functioning 
 
A stepwise multiple linear regression analysis was conducted with the community recruited CHR-
positive participants to determine if performance in the neurocognitive tests at baseline could 
predict CAARMS severity, global, role and social functioning. Only neurocognitive tests where 
there was a statistically significant difference between YouR HC or BACS standardised controls 
and CHR-positive participants were included (verbal memory, working memory, motor speed, 
processing speed, composite score, attention and emotion recognition response time).  Table 5 
outlines the findings from the regression analysis.  
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*p<0.05, ** p<0.01, RT = response time 
 
Table 5: Linear Regression for the Effects of Neurocognitive Performance on Clinical 
Characteristics at Baseline in Community Recruited CHR-positive Participants 
  
B (95% CI) 
 
Standard Error B 
 
β 
 
R2 
 
F 
 
p 
 
CAARMS severity 
 
Model 1 
    
0.04 
 
3.98 
 
0.05 
 
Constant  
 
27.52  (24.27, 30.76) 
 
1.64 
    
 
ERT (RT) 
 
1.97 (0.01, 3.82) 
 
0.96 
 
.19* 
   
 
GAF score 
 
Model 1 
    
0.07 
 
8.17 
 
0.05 
 
Constant  
 
60.03 (57.65, 62.41) 
 
1.20 
    
 
Verbal 
memory 
 
2.25 (0.69, 3.81) 
 
0.79 
 
.27** 
   
 
Role Functioning 
 
Model 1 
    
0.04 
 
4.49 
 
0.04 
 
Constant  
 
7.59 (7.40, 7.78) 
 
0.10 
    
 
CS 
 
0.16 (0.01, 0.32) 
 
0.08 
 
.20* 
   
 
Social Functioning 
 
Model 1 
    
0.08 
 
9.61 
 
<0.01 
 
Constant 
 
7.61 (7.42., 7.80) 
 
0.10 
    
 
CS 
 
0.24 (0.09, 0.40) 
 
0.08 
 
.29** 
   
 
Model 2 
    
0.12 
 
7.12 
 
<0.01 
 
Constant  
 
 
7.67 (7.47, 7.87) 
 
0.10 
    
 
CS 
 
0.20 (0.05, 0.36) 
 
0.08 
 
.24** 
   
 
EI (RT) 
 
-0.13 (-0.25, -0.02) 
 
0.06 
 
-.19* 
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The RT from the ERT explained 4% of the variability in CAARMS severity scores. Higher 
CAARMS severity scores predicted slower response times. Verbal memory score accounted for 7% 
of the variance in GAF score, with high GAF score predicting higher verbal memory scores. The 
BACS composite score (CS) explained 4% and 8% of the variability of role and social functioning, 
respectively. Both CS and ERT (RT) together accounted for 12% of the variance in social 
functioning.  
Following the statistically significant findings from the ERT an additional stepwise multiple linear 
regression analysis was conducted with the emotion specific response times (happy, fear, angry, 
sad and no emotion). Happy (RT) was found to account for 7% of the variance in CAARMS 
severity with slower response times predicting a higher severity. Angry (RT) accounted for 11% of 
the variance social functioning with slower response times predicting lower functioning. See Table 
6 for a full summary of the emotion specific (RT) regression analysis.    
Table 6: Effects of Emotion Specific (RT) on Clinical Characteristics at Baseline for 
Community Recruited CHR-positive Participants 
*P<0.01, RT = response time 
  
B (95% CI) 
 
Standard 
Error B 
 
β 
 
R2 
 
F 
 
p 
 
CAARMS Severity 
 
Model 1    
 
0.07 
 
7.61 
 
<0.01 
 
Constant 
 
26.77 (23.43, 30.11) 
 
1.68     
 
Happy (RT) 
 
3.06 (0.86, 5.27) 
 
1.11 
 
.26*    
 
Social Functioning 
Model 1    0.10 11.16 <0.01 
Constant 7.62 (7.43, 7.81) 0.10     
Anger (RT) -0.20 (-0.32, -0.08) 0.60 -.31*    
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7.7 Follow-up Analysis 
 
Participants were assessed at 3 or 6 month intervals for up to 36 months. The following analysis 
examined follow-up data of CHR-positive participants, primarily from the 12-month assessments 
(N = 41, 84%). If data was not available at 12 months, it was taken from the 9-month assessment 
(N = 8, 16%).  There were 33 (47%) CHR-positive participants who met the ARMS group at 
baseline but not follow-up (remission group), 16 (23%) who met the ARMS criteria at baseline and 
follow-up (non-remission group), 16 (23%) participants only met basic symptoms criteria at 
baseline and no CAARMS criteria at FU (no change group), 4 (6%) participants only met BS 
criteria at baseline but met ARMS criteria at FU and 1 (1%) participant who met psychosis 
threshold by FU.  There were 55 participants who were included at baseline analysis that could not 
be included in the follow-up analysis because they were still awaiting their 9 or 12-month 
assessment (N = 46) or withdrew/disengaged (N = 9) from the study.  
7.8 Missing Data 
 
Participants included in the following analysis with only a 9-month assessment did not have a 
social and role functioning score because this was only administered at the 12-month assessment. 
In total, there were 6 remitters and 3 non-remitters without a social and role functioning score at 
follow-up.  
7.9 Demographic, Symptomatic and Functioning Characteristics 
 
Between group comparisons (see Table 6) of remitters (CHR-R) and non-remitters (CHR-NR) 
found no statistically significant differences in GAF or social and role functioning scores at 
baseline or follow-up. At baseline in the remitter group 6 (18%) met the criteria for poor role 
functioning and 5 (15%), poor social functioning. By comparison in the non-remitter group 3 
(19%) met the criteria for poor role functioning and 4 (25%), poor social functioning.  At follow-
up, 3 (11%) and 8 (30%) of the remitters met the criteria for poor role and social functioning, 
respectively by comparison to 2 (15%) and 3 (23%) of the non-remitters. CHR-NR had a lower 
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CAARMS severity score at baseline than CHR-R but this did not reach statistical significance (p = 
0.07).  
The Wilcoxon Signed Ranks test, nonparametric alternative to the paired samples t-test was used to 
compare baseline and follow-up clinical characteristics within the CHR-R and CHR-NR groups. 
There were no significant differences between baseline and follow-up GAF scores in remitters (z = 
-0.411, p = 0.68) and non-remitters, (z = -0.48, p = 0.65). Similarly, there were no statistically 
significant differences within either group for role functioning (remitters, z = -1.31, p = 0.23 and 
non-remitters, z = -0.69, p = 0.61) or social functioning (remitter, z = -0.64, p = 0.56 and non-
remitter, z = -0.55, p = 0.82).  Both remitters (z = -5.00, p <0.01) and non-remitters (z = -3.24, p 
<0.01) had improvements in their CAARMS severity scores from their baseline to follow-up 
assessments.  
7.10 Neurocognitive Characteristics  
 
Baseline scores from the BACS and Penn CNB were calculated for CHR-R and CHR-NR and 
reported in Table 5. Following an independent t-test, CHR-NR performed poorer than CHR-R with 
medium effect sizes in the motor speed task (g = 0.71) and performed better in the attention (RT) 
task (g = -0.60) with medium effect sizes. A Mann-Whitney U analysis found that the CHR-NR 
group had more pronounced impairments in emotion recognition (RT) with a small effect size (r = 
0.32), specifically for ‘happy’ faces with a large effect size (g = -0.90). A statistically significant 
difference in emotion recognition (RT) remained for CHR-NP by comparison to HC with a large 
effect size (g = -0.60). See Appendix D for a full report of the emotion specific comparisons 
between HC, CHR-R and CHR-NR.  
Additionally, as illustrated in Figures 3 and 4, the CHR-R group performed more similarly to the 
CHR-negative group and HC in the verbal memory and executive functioning tasks in the BACS 
together with the emotion recognition (RT) and working memory (A) in the Penn CNB. 
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                        Table 7: Baseline and Follow-up Clinical and Neurocognitive Characteristics of CHR-R and CHR-NR 
 N  CHR-R  N  CHR-NR  Statistic p 
  Demographics    
Age (mean ± SD) 
 
33 21.64 ± 4.14 16 21.94 ± 4.36 U = 249.5 0.76 
Female (N, %) 33 27 (82) 16 12 (75) X2 = 0.31 0.71 
Current Psychological Intervention (N, %) 33 7 (21) 16 3 (19) X2 = 0.69 0.68 
Medication (N, %) 
 
Anti-psychotic 
 
Mood stabiliser 
 
Anti-depressant 
 
Other 
 
Multiple 
33 16 (48) 
 
1 (3) 
 
1 (3) 
 
6 (18) 
 
2 (6) 
 
6 (18) 
16 8 (50) 
 
0 (0) 
 
0 (0) 
 
2 (12.5) 
 
3 (19) 
 
3 (19) 
X2 = 0.01 
 
 
 
 
 
 
1.00 
 
 
 
 
 
NART: Full IQ 33 113.56 ± 12.52 16 110.81 ± 9.01 U = 236.50  0.67 
NART: Verbal IQ 33 110.03 ± 6.48 16 109.00 ± 8.29 t(46) = 0.47 0.64 
NART: Performance IQ 33 111.09 ± 6.13 16 110.19 ± 7.91 t(46) = 0.44  0.66 
  Clinical Characteristics    
BL: CAARMS severity (median, range) 33 29 (4 – 66) 16 44 (12 – 52) U = 179.50 0.07 
FU: CAARMS severity (median, range) 33 8 (0 – 42) 15 27 (9 – 50) U = 62.00 <0.01 
BL: GAF (median, range) 33 60 (40 – 87) 16 58 (43 – 80) U = 228.00 0.45 
FU: GAF (median, range) 31 58 (21 – 88) 16 55.50 (38 – 78) U = 193.50 0.22 
BL: Role Functioning (median, range) 33 8 (5 – 9) 16 7.50 (6 – 9) U = 221.50 0.34 
FU: Role Functioning (median, range) 27 8 (5 – 9) 13 8 (4 – 8) U = 127.50 0.13 
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Table continued N CHR-R N CHR-NR Statistic p 
BL: Social Functioning (median, range) 33 8 (5 – 10) 16 8 (6 – 9) U = 223.00 0.36 
FU: Social Functioning (median, range) 27 8 (5 – 10) 13 8 (6 – 8) U = 152.00 0.47 
  BACS    
Verbal Memory  (mean ± SD) 33 -0.06 (1.40) 16 -0.74 (1.49) U = 186.50 0.10 
Working Memory (mean ± SD) 33 -0.26 (0.92) 16 -0.45 (1.11) t (47) = 0.63 0.53 
Motor Speed (mean ± SD) 33 -0.89 (1.22) 16 -1.78 (1.24) t (47) = 2.37  0.02 
Verbal Fluency (mean ± SD) 33 0.17 (1.02) 16 0.26 (1.27) t (47) = -0.28  0.78 
Processing Speed (mean ± SD) 33 -0.09 (0.95) 16 -0.28 (1.38) t (47) = 0.55  0.59 
Executive Functioning (mean ± SD) 33 0.23 (0.91) 16 0.04 (1.00) U = 227.50 0.43 
Composite Score (mean ± SD) 33 -0.20 (1.14) 16 -0.78 (1.43) U = 204.00 0.20 
  Penn CNB    
ERT (mean ± SD) 33 -0.06 (0.84) 16 -0.34 (1.38) U = 246.50 0.71 
ERT  (RT) (mean ± SD) 33 -0.38 (1.34) 16 -1.80 (2.35) U = 159.00 0.02 
Working Memory  (mean ± SD) 32 -0.26 (1.05) 16 -1.19 (2.69) U = 239.50 0.71 
Working Memory (RT) (mean ± SD) 32 0.07 (0.74) 16 -0.09 (0.83) t (46) = -0.67  0.50 
Attention (mean ± SD) 32 -0.79 (2.72) 16 -1.46 (4.62) U = 244.50 0.50 
Attention (RT) (mean ± SD) 33 -0.09 (0.95) 16 0.44 (0.67) t (47) = 0.21  0.05 
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Abbreviations: VM = verbal memory, WM = working memory, MS = motor speed, VF = verbal fluency, PS = processing speed, EF = executive functioning, CS = composite score 
Figure 3: Z-scores of BACS neurocognitive performance with CHR-R and CHR-NR 
-2
-1.5
-1
-0.5
0
0.5
1
VM WM MS VF PS EF CS
z-
sc
or
es
BACS: Neurocognitive Domains
CHR-negative CHR-R CHR-NR HC
52 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: ERT = emotion recognition task, ERT-RT = emotion recognition task (RT), WM = working memory, WM = working memory (RT), ATT = attention, ATT–RT = attention (RT) 
Figure 4: Z-scores of Penn CNB neurocognitive performance with CHR-R and CHR-NR 
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Chapter 8  
Discussion 
 
8.1 Summary of Main Findings 
 
The following will summarise the main findings from the statistical analyses addressing the 
hypotheses discussed in Chapter 5 before discussing the results of the study as a whole whilst 
considering thoughts and findings from previous research.  
The primary aim of the current research project was firstly to investigate if neurocognitive 
impairments typically observed in clinically recruited CHR individuals could be extended to 
those recruited from the general population and secondly to explore their relationship with 
positive symptom severity and functioning. In line with Hypothesis 1, community recruited 
CHR-participants displayed cognitive impairments by comparison to healthy controls but not to 
the same extent as the clinically recruited CHR-participants. Consistent with previous studies 
using clinically recruited participants, the community recruited group were impaired 
specifically in the domains of motor speed, processing speed, emotion recognition (RT), 
attention and in the neurocomposite score by comparison to healthy controls. Furthermore, 
positive psychotic symptom severity was significantly associated with emotion recognition 
(RT), specifically for ‘happy’ faces, contrary to Hypothesis 2 that predicted that positive 
symptom severity would be independent from cognition. As expected by Hypothesis 3 
neurocognitive test performance was significantly associated with functioning, specifically 
performance in verbal memory predicted the GAF score while the neurocomposite score 
explained variances in social and role functioning. In a second model, variances in social 
functioning were further explained with the addition of the emotion recognition (RT), 
specifically for ‘angry’ faces. 
Neurocognitive impairments were also explored in CHR-negative participants who scored 
below the threshold CHR criteria but were characterised by psychiatric comorbidities to 
investigate the contribution of non-psychotic symptomatology to cognitive impairments. 
Contrary to Hypothesis 4, there were no statistically significant differences in neurocognitive 
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functioning between the CHR-negative group and healthy controls. Additionally, CHR-positive 
participants were statistically significantly impaired by comparison to CHR-negative 
participants in processing speed.   
The third aim investigated the association between baseline neurocognitive functioning on 
clinical outcome at 12 months. Harmonious with Hypothesis 5 those who did not remit from 
their baseline APS had more pronounced deficits at baseline in motor speed and emotion 
recognition (RT) than those who remitted. Furthermore, the CHR-R group performed more 
similarly to the healthy controls and CHR-negative group in the verbal memory and executive 
functioning tasks in the BACS together with the emotion recognition (RT) and working 
memory (accuracy score) in the Penn CNB.  
 
8.2 Description of Sample 
 
8.2.1. Symptomatology and Functioning  
 
The CHR-positive group had significant impairments in social and role functioning by 
comparison to HC. The median score for both scales reflects ‘good functioning’ however this 
can be misleading as the functioning scores ranged from ‘major impairment’ to ‘superior 
functioning’ (Cornblatt et al., 2007). Similarly, the median GAF score was 58 representing 
‘moderate symptoms’ but again scores ranged from ‘inability to function in almost all areas’ to 
‘no symptoms’ (Yung et al., 2006) highlighting the heterogeneity with CHR samples.   
Following the distinction in recruitment pathways, it was found that the clinical sample had 
significantly lower role functioning but not social functioning than those from the community. 
There were no significant differences between these two groups in the severity of positive 
symptoms or GAF scores. However, these statistical comparisons were underpowered due to 
the small number of clinically recruited CHR-participants so results have to be interpreted with 
caution. A non-statistical comparison of these results supports previous findings that those 
recruited clinically had a higher positive symptom severity and lower levels of functioning 
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(Mills et al., 2017). More demographically matched CHR participants from clinical pathways 
would have to be recruited to determine if these observations were statistically significant.  
 
Similar to findings in clinically recruited populations (Fusar-Poli et al., 2012), the community 
recruited CHR-positive participants in the current study were characterised by a high 
prevalence of non-psychotic disorders, primarily depression and anxiety. Furthermore, three 
quarters of the community recruited CHR-positive participants reported seeking psychological 
intervention which supports the notion that community recruited CHR-participants should not 
be viewed as a non-help seeking population (Mills et al., 2017).  
 
The CHR-negative group had statistically significantly higher social, role and global 
functioning compared to the CHR-positive group. Although one of the reasons the inclusion of 
this group was to address the influence of comorbid psychiatric disorders the CHR-negative 
group had a lower prevalence of these disorders so the results have to be interpreted with 
caution.  At present, it cannot be concluded that positive psychotic symptomatology uniquely 
contributes to poor functioning in the CHR group in the current study.  However, previous 
studies have consistently associated the presence of non-psychotic disorders with poor 
functional outcomes in CHR populations (Lin et al., 2015; Rutigliano et al., 2016) 
 
8.2.2 Neurocognitive Characteristics 
 
CHR-positive participants compared to HC had specific impairments in motor speed, 
processing speed, emotion recognition (RT) and attention in addition to a lower composite 
score derived from the BACS. Motor speed was the most pronounced deficit in CHR-positive 
participants which is consistent with evidence that illustrates early motor abnormalities in 
children who develop ScZ in adulthood (Dickinson, Laurens, Cullen & Hodgins, 2012). 
However, although motor impairments are viewed as a core feature of ScZ (Morrens et al., 
2006) less research is available for at-risk samples. Studies that have independently assessed 
this domain report mixed findings, with some reporting deficits (Carrión et al., 2011; Niendam 
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et al., 2006) and others intact abilities (Keefe et al., 2006; Woodberry et al., 2010). Fewer 
studies have utilised the token motor test used in the current analysis but two recent studies 
have reported impairments by comparison to healthy controls in UHR participants using this 
task (Allot et al., 2018; Ohmuro et al., 2018) suggesting its possible utility in detecting 
impairments in at-risk groups.  
Moderate impairments in the CHR-positive group by comparison to HC were observed for 
processing speed assessed using the DSST supporting consistent findings from previous 
research (e.g. Hauser et al., 2017; Pukrop et al., 2010; Seidman et al., 2010). Moreover, 
impairments in processing speed were also observed in the CHR-positive group by comparison 
the CHR-negative group however as the CHR-negative group had a lower prevalence of non-
psychotic disorders it cannot be concluded that deficits in processing speed are unique to 
positive psychotic symptomatology. Further studies would have to include more CHR-negative 
participants with comorbid psychiatric disorders are needed to investigate this further.  
Performance in the DSST and token motor task were found to be positively correlated in both 
HC and CHR-positive participants but not CHR-negative participants. The finding between HC 
and CHR-positive participants supports previous reports from individuals with ScZ and healthy 
controls (Keefe et al., 2004). Although there has been an argument to delineate motor speed 
from processing speed (Morrens et al., 2006) performance between these specific tasks appears 
to be mediated by a shared underlying factor. 
A significant impairment in the neurocomposite score from the BACS supports the notion put 
forward by Gold and colleagues (2009) that impairments in composite scores reflect the 
contribution of deficits in individual tasks rather than an impaired general cognitive ability 
factor as a number of tasks in the neurocognitive testing battery were preserved in CHR-
positive participants. Deficits in verbal memory, verbal fluency, working memory and 
executive functioning were not found although they are widely reported in previous research 
(e.g. Fusar-Poli et al., 2012; Hauser et al., 2017). Impairments in these domains have been 
associated with transitions to frank psychosis (Carrión et al., 2018; Fusar-Poli et al., 2012). As 
the current CHR-positive sample had only one transition to frank psychosis within the 12-
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month follow-up this may be reflected in the lack of positive findings in these domains. High 
levels of educational attainment in the CHR- positive group may have also contributed to 
negative findings as previously this has been suggested to act as a protective factor, especially 
for verbal fluency (Keefe et al., 2008).  
From the Penn CNB, CHR-positive participants had a significantly slower response time in the 
emotion recognition task but an intact accuracy score. This suggests that this group has an 
impairment in processing facial information but participants are able to compensate by slowing 
down their responses to achieve high accuracy scores. These findings in the CHR-positive 
group are not consistent with previous studies that have reported accuracy impairments 
(Addington et al., 2008; Amminger et al., 2011; Comparelli et al., 2013; Kohler et al., 2014) 
but no differences in reaction time (Glenthøj et al., 2018) in CHR groups by comparison to 
healthy controls. However, abnormal neural activation has been recorded in a small number of 
UHR participants who exhibited intact behavioural responses during an emotion discrimination 
task (Seiferth et al., 2008) suggesting difficulties may be present in at-risk samples but these 
cannot always be captured by accuracy scores.  
Further analysis to identify impairments in specific facial expressions of emotion found 
significantly slower response times for ‘happy’ faces within the CHR-positive group by 
comparison to healthy controls. Previous studies have highlighted impairments only in negative 
emotions including ‘sad’, ‘fear’ and ‘disgust’ faces (Amminger et al., 2011; Comparelli et al., 
2013) but the results from the current analysis suggest processing impairments may also be 
present for positive emotions. Additionally, the CHR-positive group did not present with 
significant impairments in accuracy or reaction time for facial expressions that conveyed ‘no 
emotion’. This does not support previous studies that have reported a tendency for UHR 
participants and unaffected relatives of individuals with ScZ to attribute negative emotions to 
neutral faces (Allot et al., 2014; Eack et al., 2010; van Rijn et al., 2011).   
Attention was also significantly impaired in CHR-positive participants by comparison to HC. 
Attention has been argued to be a stable vulnerability marker in at-risk populations (Francey, 
Jackson, Phillips, Wood, Yung & McGorry, 2005); Lencz, Smith, McLaughlin, Auther, 
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Nakayama, Hovey & Cornblatt, 2006) as deficits are more pronounced in individuals who later 
transition to psychosis compared to those who do not (Seidman et al., 2016). The results from 
the current study support previous findings that highlight its centrality to the CHR state (Bora 
et al., 2014; Fusar-Poli et al., 2012; Hauser et al., 2017). 
8.3 Neurocognition in Community and Clinically Recruited CHR 
Groups 
 
Following the distinction of recruitment pathways within CHR-positive participants no 
statistically significant differences in neurocognitive performance were revealed between those 
recruited clinically and those from the general population. When statistical comparisons were 
made between clinical and community CHR groups with healthy controls clinically recruited 
CHR-participants had large impairments motor speed, processing speed and the composite 
score. However, due the small number of clinically-recruited CHR-participants these analyses 
are underpowered and thus need to be interpreted with caution. 
In support of Hypothesis 1 the CHR-community group presented with moderate effect sizes in 
motor speed, processing speed and in the neurocomposite score in addition to small effect sizes 
in emotion recognition (RT) and attention compared to healthy controls. Previous meta-
analyses using clinically recruited CHR-participants have reported similar moderate effect sizes 
to those observed in the current community recruited group in processing speed assessed using 
the DSST (Fusar-Poli et al., 2012; Hauser et al., 2017) although larger impairments have also 
been reported (Bora et al., 2014). Similar sized deficits in attention, assessed using the CPT, 
have also been reported in clinical populations (Bora et al., 2014; Fusar-Poli et al., 2012; 
Hauser et al., 2017). These findings suggest that neurocognitive impairments in processing 
speed and attention observed in clinical groups from the previous studies may be extended to 
CHR individuals in the general population supporting growing evidence that deficits may be an 
endophenotype of psychosis. As discussed, the emotion recognition (RT) has not been widely 
studied but the impairment revealed in the current analysis highlights its potential association 
with attenuated psychotic symptoms in individuals in the general population.  
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8.4 Association between Neurocognition and Positive Psychotic 
Symptom Severity 
 
Within the CHR-community group the association between positive symptom severity and 
neurocognitive impairment was examined. Hypothesis 2 expected that positive psychotic 
symptom severity would be independent from cognitive functioning. Although a regression 
analysis indicated that neurocognitive assessments overall were not a strong predictor of the 
positive symptom severity there was one statistically significant contributor. The response time 
taken in the emotion recognition task, with slower responses predicting higher severity scores 
accounted for 4% of the variance. Specifically, reaction times for ‘happy’ facial expressions of 
emotion explained 7% of the variance with slower reaction times predicting higher severity 
scores. This is partially supported by previous findings that have reported an association 
between emotion recognition and the degree of attenuated positive psychotic symptoms 
(Glenthøj et al., 2018) and transitions to frank psychosis (Allot et al., 2014) in UHR 
populations.  However, other studies have failed to find a significant association between 
emotion recognition and positive psychotic symptomatology but posit that deficits contribute to 
the creation and exacerbation of delusions (Amminger et al., 2012).  
Overall, the variance accounted for by emotion recognition (RT) was relatively low suggesting 
that other factors contribute more to the severity of positive symptoms in community recruited 
CHR groups. Additionally, non-significant findings for other neurocognitive tests are supported 
by previous research, suggesting their relative independence in the severity of positive 
symptoms in both clinical and community recruited groups (Niendam et al., 2006; Ventura, 
Helleman, Thames, Koellner & Nuechterlein, 2009).   
8.5 Association between Neurocognition and Functioning 
 
In support of Hypothesis 3 significant associations were found between neurocognitive tasks 
and measures of functioning. Verbal memory significantly predicted 7% of the variance in 
GAF score, with a better performance predicting a higher score supporting previous studies that 
investigated social and occupational functioning and quality of life outcomes (Lin et al., 2011) 
and social functioning (Niendam et al., 2006) in clinically recruited CHR individuals. This 
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finding additionally complements a previous study that observed that verbal memory alongside 
processing speed, reasoning and problem solving had the strongest correlation with real world 
functioning (Keefe, Poe, Walker & Harvey, 2006).  
The composite score from the BACS explained 4% and 8% in the variances in role and social 
functioning respectively, with higher scores predicting better functioning. This finding is 
similar to that of Carrión and colleagues (2011) who reported that the neurocomposite score 
they used explained 8% and 5% of the variance in social and role functioning, respectively. The 
composite score combined with ERT (RT) in a second predictive model explained 12% of the 
variance in social functioning. Following a regression analysis investigating specific emotional 
expressions, the response time for identifying ‘anger’ faces explained 10% of the variance in 
social functioning, with slower responses predicting lower functioning. This supports the 
notion that emotion recognition is integral to social cognition and functioning (Amminger et 
al., 2012) and that difficulties interpreting emotional expressions can cause stress and make it 
challenging to engage in social interactions and communication (Bediou et al., 2007) in turn 
negatively impacting social and role functioning.  
Additionally, results from the regression analysis highlight a possibility to why significant 
differences were not identified between CHR-positive participants and HC in verbal memory 
and the response time for ‘angry’ faces, as deficits in these tasks appear to be associated with 
poorer social and role functioning which was not experienced by the majority of the CHR-
positive group. 
8.6 Neurocognition in CHR subgroups  
 
Comparisons within the CHR-positive group of individuals who met either the BS, UHR or 
BS+UHR criteria revealed subtle, non-significant differences in neurocognitive  performance 
between the BS and UHR groups with the UHR performing worse. This finding is supported by 
previous studies that have reported small, non-significant neurocognitive impairments in 
studies that used the BS criteria compared to those who used the UHR (Fusar-Poli et al., 2012). 
Another study reported that those in the late prodromal stage had deficits in all neurocognitive  
domains assessed compared to the specific impairments in executive control/processing speed 
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observed in those in the early prodromal stage suggesting that certain deficits can be observed 
very early and progressive impairments occur towards the end of the prodrome (Fromman et 
al., 2011). In the current study, UHR participants were impaired by comparison to HC in motor 
speed, processing speed and attention/vigilance while BC participants were only significantly 
impaired in motor speed suggesting that this could be a marker for early psychosis risk. 
8.7 Follow-up Analysis 
 
8.7.1 Description of Sample 
 
By the 12 month follow-up assessment, 66% of the CHR-positive participants who met the 
ARMS at baseline were in remission, 32% maintained these symptoms and 2% transitioned to 
psychosis. Compared to previous longitudinal studies using exclusively clinically recruited 
participants the number of transitions is dramatically lower (Fusar-Poli et al., 2012; Yung & 
McGorry, 2004) suggesting that CHR-participants in the current study, who were recruited 
mainly from the general population, were not enriched for psychosis risk. Although there is a 
considerable number of participants still experiencing ongoing attenuated psychotic symptoms 
the majority were in remission suggesting that the sample was diluted by a high number of false 
positives. The CHR criteria focuses on positive symptomatology which alone has a low to 
moderate predictive power of psychosis onset (Klosterkotter et al., 2001; Yung et al., 2005). As 
previous studies have highlighted that transitional psychotic experiences are commonly 
experienced by healthy individuals (van Os et al., 2001; Morey et al., 2005; Rössler et al., 
2007) using only positive psychotic symptomology risks incorrectly labelling healthy 
individuals as CHR.  The high number of non-transitions and remissions in the current study 
compared to previous studies suggests that recruiting from the general population over 
prodromal services increases this risk further.  
As a high number of individuals who experience a first episode of psychosis are not seen by 
prodromal services (Ajnakina et al., 2017) it remains important to look out with prodromal 
services for individuals at risk. To increase the predictive power additional criteria may have to 
be met to minimise the dilution of samples. In their review Fusar-Poli and colleagues (2012) 
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reported that the following clinical variables were observed in the NAPLS (Seidman et al., 
2010) and PACE (Thompson, Nelson & Yung, 2011) clinics to be associated with transitions to 
psychosis: high unusual thought content scores, low functioning and genetic risk with 
functional decline. Additionally, cognitive functioning may also improve predictive power 
alongside clinical variables (Lencz et al., 2006; Riecher-Rössler et al., 2009). 
8.7.2 Symptomatology and Functioning  
 
At 12 months, as would be expected non-remitters reported a statistically significantly higher 
positive symptom severity score than non-remitters. However, there was an overlap in the 
range of scores suggesting that some individuals in both groups were straddling the boundary 
between threshold and subthreshold attenuated psychotic symptoms. Comparisons at baseline 
found no statistically significant differences in positive symptom severity between remitters 
and non-remitters. Although, subtle non-significant differences were observed with non-
remitters having a higher positive symptom severity score suggesting that those who present 
with a higher severity at intake are more likely to remain symptomatic by 12 months. This 
supports previous research that has highlighted psychotic symptom severity to be a reliable 
characteristic differentiating converters from non-converters (Fusar-Poli et al., 2013) 
specifically at the baseline assessment (Hengartner et al., 2017). From baseline to follow-up 
both groups displayed an improvement in positive psychotic symptom severity. Previous 
research observing symptom severity over a longer period with close follow-up assessment 
intervals have reported a non-linear progression from attenuated to frank psychotic symptoms 
reporting that participants may appear to be in remission but soon develop threshold symptoms 
(Hengartner et al., 2017). It may be likely that the group allocations in the current study do not 
reflect the long term transitional outcome of the group.  
The current study explored the heterogeneity of outcome in CHR-participants by distinguishing 
between ‘remitter’ and ‘non-remitter’ groups, however this may have been too simplistic.  A 
recent study argued that more nuanced groups need to be constructed to accurately reflect the 
different clinical trajectories taken by at-risk groups (Polari et al., 2018). Polari and colleagues 
(2018) defined recovery as being in remission from APS for over 6 months. From their study 
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they reported that 20% of their participants had a reoccurrence of their UHR status after 
remission but before recovery and 4% had a relapse after recovery at 4 assessments over 12-
months. This highlights the fluctuating state of psychotic symptoms within CHR groups and 
implies remitters and non-remitters in the current study may have experienced remission and 
relapse within this time frame and their symptoms at 12 months may not be an accurate 
representation of their clinical status. As more follow-up assessments are completed within the 
CHR-positive group it would be interesting to study closer the clinical trajectory of community 
recruited participants over a longer period of time to determine if they complement those 
observed in clinical populations (Polari et al., 2018). Identifying the long term pathways of 
CHR individuals is important for research and clinical practice as it could help to identify the 
underlying biopsychosocial predictors for each trajectory to better direct treatment. 
At 12 months remitters and non-remitters had similar psychosocial functioning scores that did 
not change significantly from their baseline to follow-up assessment. Both groups reported a 
median GAF score that reflected ‘moderate symptoms’ and a social and role functioning score 
that represented ‘good functioning’, although there was a considerable range of functioning 
between participants in both groups. Furthermore, both groups had similar frequencies of 
participants who met the criteria for poor functioning suggesting that CHR individuals may still 
have unfavourable outcomes regardless of their positive symptom status at 12 months, 
supporting previous findings that have highlighted that non-psychotic outcomes are not 
synonymous with good functioning (Lin et al., 2015; Polari et al., 2018).   
There is accumulating evidence that neurocognitive impairments contribute to poor functional 
outcomes regardless of transitional status in clinically recruited CHR-participants (Lin et al., 
2011). In the current study there were not enough CHR individuals who met the criteria for 
‘poor functioning’ by 12 months to compare baseline neurocognitive impairments. As more 
follow-up data is gathered from the YouR study it would be interesting to identify if ‘poor 
functioning’ was as common an outcome for community recruited participants as it was for 
clinically recruited participants and furthermore explore the influence of neurocognitive 
impairments at baseline on functioning outcome.  
64 
 
8.7.3 Neurocognitive Characteristics 
 
At baseline non-remitters were statistically significantly more impaired in motor speed and 
emotion recognition (RT) by comparison to remitters. Furthermore, remitters but not non-
remitters presented with a similar performance to healthy controls and CHR-negative 
participants in verbal memory, working memory, executive functioning and emotion 
recognition. These findings support previous results that observed heterogeneity in 
neurocognitive performance at baseline between remitters and non-remitters (Lee et al., 2014) 
and suggests that preserved neurocognitive functioning at baseline could be a marker for 
remission. A previous study highlighted a statistically significant association between 
immediate verbal memory and remission from psychosis (Simon et al., 2012). Due to small 
sample sizes the utility of neurocognitive functioning in the prediction of remission from 
psychosis could not be investigated. Overall, one interpretation of the above findings is that 
preserved neurocognitive functioning acts as a protective buffer against ongoing psychotic 
symptoms alternatively however it could be argued that remitters were experiencing 
transitionary psychotic experiences and were never at real risk of psychosis onset.  
Remitters did not display a similar baseline performance to healthy controls in all 
neuropsychological tests. As neurocognitive performance was not re-tested at the follow-up 
assessment the neurocognitive trajectory between remitters and non-remitters is unknown. An 
earlier study reported that remitters displayed an improved performance in semantic fluency 
between baseline and follow-up whereas non-remitters performance worsened suggesting that 
semantic verbal fluency is a trait marker of psychosis (Lee et al., 2014). In the current study, 
verbal fluency at baseline was preserved in both groups so it would be insightful to investigate 
if performance deteriorated in those with increasing positive symptom severity.  
8.8. Implications of the Study 
 
The current study observed neurocognitive impairments specifically in attention, emotion 
recognition, motor speed and processing speed in at-risk of psychosis individuals recruited 
from the general population by comparison to healthy controls suggesting they are an 
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endophenotype of psychotic symptomatology. Furthermore, their association with psychosocial 
functioning highlights these domains as possible targets for intervention to improve long term 
clinical and functional outcome. Specific neurocognitive impairments were identified in at-risk 
participants by comparison to healthy controls in motor speed and emotion recognition 
following the token motor test and emotion recognition test that have not been widely used in 
previous research. Motor speed deficits have not consistently been reported in studies using the 
Finger Tapping Test (Fusar-Poli et al., 2012; Hauser et al., 2017) however, findings from the 
current analysis support growing research (Allot et al., 2018; Ohmuro et al., 2018) that suggest 
the Token Motor Test’s utility in detecting motor impairments in at-risk groups. Similarly, 
although accuracy scores from emotion recognition tests have been widely used, response times 
have not. In the current study, it was revealed that at-risk participants had significantly slower 
reaction times but not accuracy scores compared to healthy controls. Thus, it is proposed that 
slower reaction times may reflect compensatory mechanisms used in at-risk participants that 
cannot be utilised during threshold psychosis. Furthermore, reaction times in the emotion 
recognition test were found to predict positive psychotic symptom severity and social 
functioning suggesting their possible utility in predicting transitional and poor functional 
outcomes.  
The 12 month clinical outcome of CHR individuals recruited from the general population was 
also explored. Overall, the sample experienced high non-transition and remission rates 
supporting the argument that additional criteria need to be met in order to distinguish false-
positive from those at true risk. Statistically significant differences in baseline neurocognitive 
functioning specifically in motor speed and emotion recognition suggest their potential utility 
in predicting symptom remission among community recruited CHR individuals.   
8.9. Limitations of the Study  
 
The results of this analysis have to be considered with the limitations of the study in mind. 
Firstly, specific subgroups of participants had small sample sizes (clinically recruited CHR-
positive participants, remitters and non-remitters) which may limit the generalisability of these 
findings. Additionally, females were also overrepresented in all subgroups for reasons that are 
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unclear. It is important to develop different strategies to recruit more males from the 
community especially as males have been reported to experience more severe negative 
symptoms and poorer functioning (Thorup et al., 2007; Walder et al., 2013; Walker et al., 
2002).  
It is also possible that neurocognitive impairments that significantly accounted for the variance 
in functioning may have been mediated by negative symptoms (Meyer et al., 2014). As the 
current study did not assess for negative symptoms their relationship with neurocognition and 
functioning could not be investigated here.  
The SPI-A assessment was not conducted at the 12 month follow-up assessment so CHR-
positive individuals who met the BS criteria as baseline were excluded from the follow-up 
analysis. At 12 months, 16 (80%) of these individuals did not meet the ARMS criteria at 
follow-up and 4 (20%) did. It is possible that individuals who met only the BS criteria at 
baseline and not the ARMS at follow-up may have still met the criteria for BS. Furthermore, 
participants who met both the BS+UHR criteria at baseline who were seen as being in 
remission at follow-up may have continued to have met the BS criteria. This is supported by a 
previous study that reported that 12% of participants who met either the UHR or BS+UHR 
criteria at baseline met only BS symptoms at follow-up (Polari et al., 2018).  
8.10 Statistical Limitations 
 
There were some statistical limitations concerning the regression analyses. Firstly, to increase 
the power of the analyses only the neurocognitive variables that differed significantly between 
the CHR-positive and healthy controls were included. It is possible that some of the excluded 
variables may have explained some additional variance in positive psychotic symptom severity 
and measures of functioning. This was demonstrated following the statistically significant 
contribution made by ‘angry’ faces (RT) to social functioning, despite no statistically 
significant differences existing at baseline.  
Secondly, conducting a stepwise multiple regression analysis may have omitted some 
neurocognitive predictors because it increases the risk of Type II errors via suppressor effects.   
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Appendices 
 
Appendix A: Within CHR Group Comparisons of Clinically and Community Recruited Participants 
 N  HC N Community  N Clinical  df Statistic  p Significant post-hoc tests 
BL: CAARMS severity 
(median, range) 
- - 110 28.50 (0 – 72) 12 23 (14 – 54) - U = 620.50 0.74 - 
BL GAF score (median, 
range) 
- - 110 59 (21 – 95) 12 56.50 (43 – 75) - U = 566.50 0.43 - 
BL: Role functioning 
(median, range) 
- - 110 8 (4 – 9) 12 6 (6 – 9) - U = 433.00 0.04 - 
BL: Social functioning 
(median, range) 
- - 110 8 (5 – 10) 12 7.50 (6 – 9) - U = 563.50 0.39 -- 
Psychological 
Intervention  
 
Current (N, %) 
 
Past (N , %)  
- - 110  
 
15 (14) 
 
54 (49) 
 
12  
 
3 (25) 
 
6 (50) 
 
 
 
 
2 
 
 
 
 
1.56* 
 
 
 
 
0.49 
- 
≥ 1 Non-psychotic 
diagnosis (N, %) 
- - 110 104 (94.5) 12 12 (100) 1 X2 = 0.69 0.64 - 
BACS 
Verbal Memory (mean ± 
SD) 
57 0.08 ± 1.20 110 -0.27 ±  1.50 12 -0.60 ±  1.77 2, 176 1.675 0.19  
100 
 
Table continued N  HC N Community  N Clinical  df Statistic  p Significant post-hoc tests 
Working Memory (mean 
± SD) 
57 -0.22 ± 
0.77 
110 -0.25 ±  1.00 12 -0.48 ±  1.06 2, 176 0.41 0.67  
Motor Speed (mean ± 
SD) 
57 0.28 ± 1.19 110 -0.58 ±  1.42 12 -1.12 ±  1.33 2, 176 9.97 <0.01 HC vs CHR-community, 
CHR-clinical 
Verbal Fluency (mean ± 
SD) 
56 0.47 ± 1.27 110 0.25 ±  1.26 12 0.15 ±  1.22 2, 175 0.69 0.50  
Processing Speed (mean 
± SD) 
56 0.68 ± 1.13 110 0.11 ±  1.22 12 -0.68 ±  0.68 2, 176 8.55 <0.01 HC vs CHR-community, 
CHR-clinical 
Executive Functioning 
(mean ± SD) 
57 0.27 ± 0.75 109 0.20 ±  1.01 11 0.14 ±  1.13 2, 174 0.16 0.85  
Composite Score (mean 
± SD) 
57 0.41 ± 0.80 110 -0.14 ±  1.25 12 -0.86 ±  1.50 2, 29 8.53 <0.01 HC vs CHR-community, 
CHR-clinical 
Penn CNB 
Emotion Recognition 
(mean ± SD) 
57 0 ± 1 110 -0.15 ±  1.07 11 -0.19 ±  1.32 2, 175 0.42 0.66  
Emotion Recognition 
(RT) (mean ± SD) 
 
57 0 ± 1 110 -0.51 ±  1.62 11 -0.97 ±  1.39 2, 28 4.55 0.02 HC vs CHR-community  
Working Memory (mean 
± SD) 
57 0 ± 1 107 -0.31 ± 1.46 11 -0.57 ±  1.28 2, 28 2.07 0.14  
Working Memory (RT) 
(mean ± SD) 
57 0 ± 1  109 0.10 ±  0.75 11 -0.08 ±  0.84 2, 174 0.39 0.67  
Attention (mean ± SD) 57 0 ± 1 109 -0.77 ±  2.82 10 -0.78 ±  1.79 2, 28 3.86 0.03 HC vs CHR-community 
Attention (RT) (mean ± 
SD) 
57 0 ±1  110 0.16 ±  0.80 11 -0.08 ±  1.21 2, 175 0.81 0.45  
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Appendix A: CHR-subgroup Comparisons 
 HC (N = 57) BS (N = 31) UHR (N = 38) BS + UHR (N = 48) df Statistic p Significant post-hoc comparisons 
BL: CAARMS 
severity (mean ± 
SD) 
0 (0 – 12) 
 
13 (0 – 54) 23 (4 – 53) 40 (11 – 72) 3 H = 156.39 <0.01 HC vs BS, UHR, BS+UHR.  
BS vs UHR, BS+UHR.  
UHR vs BS+UHR 
BL GAF score 
(mean ± SD) 
88 (67 – 97) 63 (48 – 95) 59 (21 – 91) 53.50 (38 – 80) 3 H = 98.84 <0.01 HC vs BS, UHR, BS+UHR.  
BS vs UHR, BS+UHR.  
BL: Role 
functioning (mean 
± SD) 
9 (5 – 9) 8 (6 – 9) 8 (6 – 9) 7.50 (4 – 9) 3 H = 49.96 <0.01 HC vs BS, UHR, BS+UHR 
BL: Social 
functioning (mean 
± SD) 
9 (8 – 10) 8 (6 – 10) 8 (5 – 10) 8 (5 – 9) 3 H = 61.65 <0.01 HC vs BS, UHR, BS+UHR 
   BACS    
Verbal Memory 
(mean ± SD) 
0.08 ± 1.20 -0.27 ± 1.72 -0.47 ± 1.59 -0.18 ± 1.35 3. 81 F = 1.07 0.36  
Working Memory 
(mean ± SD) 
-0.22 ± 0.77 -0.10 ± 0.87 -0.40 ± 1.09 -0.27 ± 1.01 3, 170 F = 0.40 0.75  
Motor Speed 
(mean ± SD) 
0.28 ± 1.19 -0.53 ± 1.51 -0.75 ± 1.45 -0.61 ± 1.35 3, 170 F = 6.04 <0.01 HC vs BS, UHR, BS+UHR,  
Verbal Fluency 
(mean ± SD) 
0.47 ± 1.27 0.15 ± 0.96 0.01 ± 1.52 0.49 ± 1.16 3, 169 F = 1.75 0.16  
Processing Speed 
(mean ± SD) 
0.68 ± 1.13 0.06 ±1.25 -0.13 ± 1.25 0.14 ± 1.14 3, 170 F = 3.99 <0.01 HC vs UHR 
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Table continued HC (N = 57) BS (N = 31) UHR (N = 38) BS + UHR (N = 48) df Statistic p Significant post-hoc comparisons 
Executive 
Functioning  
(mean ± SD) 
0.27 ± 0.75 0.12 ± 1.26 -0.07 ± 1.03 0.44 ± 0.77 3, 79 F = 1.83 0.15  
Composite Score  
(mean ± SD) 
0.41 ± 0.80 -0.14 ± 1.12 -0.58 ± 1.62 0.04 ± 1.02 3, 79 F = 4.82 <0.01 HC vs UHR 
   Penn CNB    
Emotion 
Recognition  
(mean ± SD) 
0 ± 1 -0.05 ±1.01 -0.18 ± 1.24 -0.20 ± 1.03 3, 169 F = 0.33 0.80  
Emotion 
Recognition (RT) 
(mean ± SD) 
0 ± 1 -0.44 ± 1.57 -0.45 ± 1.19 -0.69 ± 1.90 3, 80 F = 0.35 0.79  
Working Memory 
(mean ± SD) 
0 ± 1 -0.18 ± 1.26 -0.55 ± 1.83 -0.27 ± 1.18 3, 81 F = 0.96 0.42  
Working Memory 
(RT) (mean ± SD) 
0 ± 1  0.17 ± 0.62 -0.11 ± 0.59 0.17 ± 0.91 3. 90 F = 1.91 0.13  
Attention (mean ± 
SD) 
0 ± 1 -0.65 ± 1.75 -1.77 ± 4.15 -0.05 (1.25) 3, 75 F = 2.78 0.05 HC vs UHR, UHR vs BS+UHR  
Attention (RT) 
(mean ± SD) 
0 ±1  0.85 ± 0.78 -0.14 ± 0.81 0.37 (0.84) 3, 169 F = 2.72 0.05  
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                 Appendix C: Specific Emotion between Group Comparisons 
 HC (N = 57) CHR-negative (N 
= 43) 
CHR-positive (N 
= 121) 
df Statistic  p-value  Significant post hoc 
comparisons 
Happy  0 ± 1 0.06 ± 0.84 -0.09 ± 0.86  2, 218 F = 0.65 0.52  
Happy (RT) 0 ± 1 -0.49 ± 1.30 -0.68 ± 1.37  2, 104 7.06* 0.01 HC vs CHR-positive 
Angry 0 ± 1 -0.01 ± 0.88 -0.02 ± 0.94 2, 218 F = 0.02 0.98  
Angry (RT) 0 ± 1 0.71 ± 0.94 -0.18 ± 1.63 2, 218 F = 0.67 0.51  
Fear 0 ± 1 -0.02 ± 0.70 0.05 ± 0.86  2, 218 F = 0.18 0.84  
Fear (RT) 0 ± 1 -0.12 ±1.30 -0.25 ± 2.43 2, 217 F = 1.57 0.21  
Sad  0 ± 1 -0.02 ± 0.77 0.03 ±0.99 2, 218 F = 0.06 0.94  
Sad (RT) 0 ± 1 -0.22 ± 1.31 -0.61 ± 1.88 2, 218 F = 1.52 0.22  
No Emotion 0 ± 1 0.88 ± 0.15  0.88 ± 0.15 2, 218 F = 0.14 0.87  
No Emotion (RT) 0 ± 1 0.06 ± 1.11 -0.27 ± 1.58 2, 218 F = 1.31 0.27  
                      *Welch’s F 
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Appendix B: Specific Emotion Comparisons with HC, CHR-R and CHR-NR 
*Welch  
 HC (N = 57) CHR-R (N = 33) CHR-NR (N = 16) df Statistic  p-value  Significant post hoc 
comparisons 
Happy  0 ± 1 0.03  ± 0.62 -0.38  ± 1.00  2, 103 F = 1.43 0.24  
Happy (RT) 0 ± 1 -0.61  ± 1.02 -1.83  ± 1.82 2, 34 34.92* <0.01 HC vs CHR-R, CHR-NR 
CHR-R vs CHR-NR 
Angry 0 ± 1 -0.25 ± 0.88 0.13  ± 0.92  2, 103 F = 1.11 0.33  
Angry (RT) 0 ± 1 -0.15  ± 1.37  -0.60  ± 1.63 2, 103 F = 1.48  0.23  
Fear 0 ± 1 0.18  ± 0.70  0.07  ± 0.78  2. 103 F = 0.39 0.68  
Fear (RT) 0 ± 1 -0.22  ± 1.38 -1.73  ± 3.61 2, 32 1.98* 0.15  
Sad  0 ± 1 0.05  ± 0.82  0.00  ± 0.91 2, 103 F = 0.02  0.98  
Sad (RT) 0 ± 1 -0.38  ± 1.20 -1.52  ± 2.39  2, 32 2.11* 0.14  
No Emotion 0 ± 1 0.92  ± 0.09 0.81  ± 0.20  2, 37 2.36* 0.11  
No Emotion (RT) 0 ± 1 -0.07 ±1.00 -1.03 ± 2.01 1, 19 3.23* 0.09  
